<SEC-DOCUMENT>0001299933-13-000655.txt : 20130411
<SEC-HEADER>0001299933-13-000655.hdr.sgml : 20130411
<ACCEPTANCE-DATETIME>20130411090916
ACCESSION NUMBER:		0001299933-13-000655
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20130411
DATE AS OF CHANGE:		20130411
EFFECTIVENESS DATE:		20130411

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		13755089

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>htm_47452.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> StemCells, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	April 8, 2013
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	StemCells, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-19871
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94-3078125
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	7707 Gateway Blvd, Suite 140, Newark, California
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94560
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	510.456.4000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[x]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END -->



<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><B>Item&nbsp;1.01 Entry into a Definitive Agreement.</B>
</FONT>

<P align="left" style="font-size: 11pt"><I>Silicon Valley Bank Loan</I>


<P align="left" style="font-size: 11pt">Effective April&nbsp;8, 2013, we entered into an agreement with Silicon Valley Bank (&#147;SVB&#148;) for a $10
million three-year term loan (the &#147;SVB Loan Agreement&#148;). Interest will accrue at 6.00% per annum.
For the first six months of the loan, we will only make interest payments. Beginning with the
seventh month, the loan will be amortized over 30 equal monthly payments. In addition, we will
make a final payment of $1&nbsp;million at the end of the loan term. We are permitted to prepay amounts
outstanding under the term loan, but only in whole and subject to a prepayment fee. The loan is
guaranteed by StemCells California, Inc., our wholly owned subsidiary. Net proceeds from the loan
will be used to fund our research and development programs and for general corporate purposes.


<P align="left" style="font-size: 11pt">In accordance with the terms of the SVB Loan Agreement, SVB was granted a warrant to purchase up to
293,531 shares of common stock at an exercise price of $1.7034 per share. The warrant is
exercisable for ten years from the date of issuance.


<P align="left" style="font-size: 11pt"><I>CIRM Loan</I>


<P align="left" style="font-size: 11pt">Effective April&nbsp;9, 2013, we entered into a loan agreement with the California Institute for
Regenerative Medicine (&#147;CIRM&#148;) for approximately $19.3&nbsp;million to fund preclinical research in
Alzheimer&#146;s disease (the &#147;CIRM Loan Agreement&#148;). CIRM was established by the voters of the State
of California pursuant to Proposition 71 to advance the biotech industry in California through
grants and loans for stem cell research, research facilities and other vital research
opportunities. The loan was made pursuant to a research award by CIRM&#146;s governing board in
September&nbsp;2012 under CIRM&#146;s Disease Team Therapy Award program (RFA 10-05).


<P align="left" style="font-size: 11pt">A stated aim of our CIRM-funded research project is to file, within a four-year project period, an
Investigational New Drug (&#147;IND&#148;) application with the U.S. Food and Drug Administration for a
clinical study of our proprietary HuCNS-SC cells as a treatment for Alzheimer&#146;s disease.


<P align="left" style="font-size: 11pt">Funds under the CIRM Loan Agreement are expected to be disbursed periodically by CIRM over the
four-year project period, although the disbursements are subject to a number of preconditions,
including the achievement of certain progress milestones and compliance with certain financial
covenants. The loan is unsecured and the term of the loan is ten years, but may be extended under
certain circumstances. Initially, the loan will bear interest at the one year LIBOR rate plus two
percent (2%); however, the interest rate will increase by 1% each year after year five. Interest
will accrue with the first disbursement of loan funds, but we will not begin paying interest until
year six. Repayment of the principal and any accrued and unpaid interest will be due and payable
at the end of the term. We can prepay the CIRM loan at our election, either in whole or in part, at
any time and without a prepayment fee. In addition, the loan is forgivable so that our obligation
to repay will be contingent upon the success of HuCNS-SC cells as a treatment for Alzheimer&#146;s
disease.


<P align="left" style="font-size: 11pt">No warrants will be issued in connection with the CIRM loan, but we will owe various success
milestone payments, in an aggregate amount of up to five (5)&nbsp;times the principal funds disbursed by
CIRM, in the event of the commercial success of HuCNS-SC cells in Alzheimer&#146;s disease.


<P align="center" style="font-size: 11pt">&#043; &#043; &#043;



<P align="left" style="font-size: 11pt">This Current Report on Form 8-K contains forward looking statements within the meaning of Section
27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act that involve substantial
risks and uncertainties. Such statements include, without limitation, all statements as to
expectation or belief and statements as to our future results of operations and our future
obligations under the loan agreements described above. Our actual results may vary materially from
those contained in such forward-looking statements because of risks to which we are subject. For
example,


<P align="left" style="font-size: 11pt"><B><I>Our indebtedness could impair our financial condition, harm our ability to operate our business,
limit our ability to raise additional funds or capitalize on acquisition or other business
opportunities.</I></B>


<P align="left" style="font-size: 11pt">In April&nbsp;2013, we entered into (i)&nbsp;a Loan and Security Agreement with Silicon Valley Bank (the &#147;SVB
Loan Agreement&#148;) and (ii)&nbsp;a Loan Agreement with the California Institute for Regenerative Medicine
(the &#147;CIRM Loan Agreement&#148;), and pursuant to these agreements we borrowed $10&nbsp;million to help
finance our operations and we will borrow over four years additional amounts of up to approximately
$19.3&nbsp;million in aggregate to fund preclinical studies in Alzheimer&#146;s disease. Pursuant to the SVB
Loan Agreement, we pledged all of our assets, other than our patents and other intellectual
property rights, and have agreed that we may not sell or assign rights to our significant patents
without the prior consent of Silicon Valley Bank (&#147;SVB&#148;). Also, pursuant to the terms of both loan
agreements, we are subject to liquidity thresholds and financial covenants and cannot engage in
certain transactions, including disposing of certain assets, incurring additional indebtedness,
declaring dividends, making certain investments in other companies, or acquiring or merging with
any other entities unless certain conditions are met or unless we receive prior approval from SVB
or the California Institute for Regenerative Medicine (&#147;CIRM&#148;), as applicable. If our lenders do
not consent to any of these actions or if we are unable to comply with these covenants, we could be
prohibited from engaging in transactions which could be beneficial to our business and our
stockholders.


<P align="left" style="font-size: 11pt">Moreover, the degree to which we are leveraged and the restrictions governing our indebtedness,
such as minimum liquidity thresholds, could have important consequences to our business, including
the following:


<P align="left" style="font-size: 11pt">&#149; it may impair our ability to incur additional indebtedness or obtain additional financing in the
future, whether through the sale of equity or otherwise, for working capital, capital expenditures,
acquisitions, general corporate purposes, or other purposes;


<P align="left" style="font-size: 11pt">&#149; our debt service obligations could limit our flexibility in planning for, or reacting to, changes
in our business and our industry; and


<P align="left" style="font-size: 11pt">&#149; our level of indebtedness could increase our vulnerability to general economic downturns and
adverse industry conditions.


<P align="left" style="font-size: 11pt"><B><I>To service our debt, we will require cash and we may not be able to raise sufficient cash flow from
operations and financing activities to satisfy these obligations or to refinance these obligations
on acceptable terms, or at all.</I></B>


<P align="left" style="font-size: 11pt">The SVB Loan Agreement has a maturity date of April&nbsp;1, 2016, and the amount borrowed will bear
interest at a coupon rate of 6.00% and there will be a final payment of $1&nbsp;million at the end of
the loan&#146;s term. The loan will be repaid in full, plus interest, over its three-year term, unless
otherwise agreed by SVB or accelerated according to the terms and conditions of the SVB Loan
Agreement. For the first six months of the loan, we will only make interest payments. Beginning
with the seventh month, we will repay the amount borrowed in thirty equal monthly installments.


<P align="left" style="font-size: 11pt">The CIRM Loan Agreement has a term of ten years, but may be extended under certain circumstances.
Initially, the loan will bear interest at the one year LIBOR rate plus two percent (2%); however,
the interest rate will increase by 1% each year after year five. Interest will accrue with the
first disbursement of loan funds, but we will not begin paying interest until year six. Repayment
of the principal and any accrued and unpaid interest will be due and payable at the end of the
term, unless otherwise agreed by CIRM or either forgiven or accelerated according to the terms and
conditions of the CIRM Loan Agreement.


<P align="left" style="font-size: 11pt">We will likely need to raise additional funds through the sale of equity or through the licensing
or divestiture of assets in order to service our debt repayment obligations. If we are unable to
generate sufficient cash flow to service our debt obligations, we may need to refinance or
restructure our debts, sell assets, reduce or delay capital investments, eliminate programs, or
restructure operations. If we are unable to implement one or more of these alternatives, we may be
unable to meet our debt payment obligations. If we are unable to repay our debts on a timely basis,
both SVB and CIRM have various contractual remedies and SVB would be able to foreclose on the
secured collateral, including our cash accounts, and take other remedies permitted under the SVB
Loan Agreement.


<P align="left" style="font-size: 11pt"><B><I>If we fail to comply with the covenants in either the SVB or CIRM Loan Agreement, we may be
required to repay any indebtedness and pay other amounts thereunder, which may have an adverse
effect on our liquidity, business prospects and stock price.</I></B>


<P align="left" style="font-size: 11pt">Our SVB Loan Agreement and CIRM Loan Agreement both include events of default, including, among
other things, payment defaults; breaches of representations, warranties or covenants; certain
bankruptcy events; and the occurrence of certain material adverse changes. Upon the occurrence of
an event of default and following any cure periods (if available), a default interest rate of an
additional 5.0% per annum may be applied to the outstanding loan balances under both loan
agreements. Under certain circumstances, both SVB and CIRM may have the right to declare all
outstanding obligations immediately due and payable. If the maturity of our indebtedness is
accelerated, we may not have sufficient funds available for repayment or we may not have the
ability to borrow or obtain sufficient funds to replace the accelerated indebtedness on terms
acceptable to us, or at all.


<P align="left" style="font-size: 11pt">Even if we are able to repay the indebtedness upon an event of default, the repayment of these sums
may significantly reduce our working capital and impair our ability to operate as planned. The
occurrence of any of these events could cause a significant adverse impact on our business,
prospects and stock price.


<P align="left" style="font-size: 11pt">All forward-looking statements attributable to us or to persons acting on our behalf are expressly
qualified in their entirety by the cautionary statements and risk factors set forth above and in
&#147;Risk Factors&#148; in Part&nbsp;I, Item&nbsp;1A of our Form 10-K for the year ended December&nbsp;31, 2012.


<P align="left" style="font-size: 11pt"><B>Item&nbsp;2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement of a Registrant.</B>


<P align="left" style="font-size: 11pt">The information set forth in Item&nbsp;1.01 of this Current Report on Form 8-K that relates to the
creation of a direct financial obligation of our company is incorporated by reference herein.


<P align="left" style="font-size: 11pt"><B>Item&nbsp;8.01 Other Events.</B>


<P align="left" style="font-size: 11pt">On April&nbsp;9, 2013, we issued a press release announcing the execution of the SVB Loan Agreement
described in Item&nbsp;1.01 of this Current Report on Form 8-K. A copy of the press release is attached
hereto as Exhibit&nbsp;99.1 and incorporated by reference herein.


<P align="left" style="font-size: 11pt">On April&nbsp;11, 2013, we issued a press release announcing the execution of the CIRM Loan Agreement
described in Item&nbsp;1.01 of this Current Report on Form 8-K. A copy of the press release is attached
hereto as Exhibit&nbsp;99.2 and incorporated by reference herein.



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->

<!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	StemCells, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	April 11, 2013
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ Kenneth Stratton
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Kenneth Stratton
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: General Counsel
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated April 8, 2013
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.2
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated April 11, 2013
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><img src="e38032-13100173129124a032_1.jpg">
</FONT>

<P align="center" style="font-size: 11pt"><B>STEMCELLS, INC. CLOSES $10 MILLION DEBT FINANCING</B>



<P align="left" style="font-size: 11pt"><B>NEWARK, CA (April&nbsp;9, 2013) </B>&#150; StemCells, Inc. (Nasdaq: STEM) today announced that it has closed a
$10&nbsp;million debt financing from Silicon Valley Bank (SVB). The loan funds will be used for general
corporate purposes, and increase the Company&#146;s December&nbsp;31, 2012 <I>pro forma </I>cash balance to $34.4
million. This total also includes $2.0&nbsp;million in net proceeds received subsequent to the end of
the year from the exercise of warrants and the sale of shares of common stock.


<P align="left" style="font-size: 11pt">&#147;We are pleased to have secured this loan from Silicon Valley Bank,&#148; said Martin McGlynn, President
and CEO of StemCells, Inc. &#147;These funds will extend our cash runway and provide us with increased
financial flexibility. Sophisticated institutions like SVB are very careful and thoughtful when
making their lending decisions, and we appreciate the confidence shown by SVB in our company.&#148;


<P align="left" style="font-size: 11pt">The loan has a three-year term and interest will accrue at 6% per annum. For the first six months,
payments will be interest only and then the loan will be amortized over 30&nbsp;months. In addition,
there will be a final payment at the end of the term equal to $1&nbsp;million. In connection with the
debt financing, the Company also issued to SVB a warrant to acquire 293,531 shares of common stock
with an exercise price of $1.7034 per share. The warrant will expire in ten years.


<P align="left" style="font-size: 11pt"><B>About StemCells, Inc.</B>


<P align="left" style="font-size: 11pt">StemCells, Inc. is engaged in the research, development, and commercialization of cell-based
therapeutics and tools for use in stem cell-based research and drug discovery. The Company&#146;s lead
therapeutic product candidate, HuCNS-SC&#174; cells (purified human neural stem cells), is currently in
development as a potential treatment for a broad range of central nervous system disorders. &nbsp;In a
Phase&nbsp;I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and durable donor-derived
myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting
a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported
positive data for the first patient cohort. The Company has also initiated a Phase I/II clinical
trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in
Alzheimer&#146;s disease.&nbsp; StemCells also markets stem cell research products, including media and
reagents, under the SC Proven&#174; brand. Further information about StemCells is available at
<U>http://www.stemcellsinc.com</U>.


<P align="left" style="font-size: 11pt"><I>Apart from statements of historical fact, the text of this press release constitutes
forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the
Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein.
These statements include, but are not limited to, statements regarding the Company&#146;s ability to
repay the loan from Silicon Valley Bank and the likely repayment terms; the expected use of the
loan funds; the development and commercialization of the Company&#146;s cell-based technologies; and the
future business operations of the Company. These forward-looking statements speak only as of the
date of this news release. The Company does not undertake to update any of these forward-looking
statements to reflect events or circumstances that occur after the date hereof. Such statements
reflect management&#146;s current views and are based on certain assumptions that may or may not
ultimately prove valid. The Company&#146;s actual results may vary materially from those contemplated in
such forward-looking statements due to risks and uncertainties to which the Company is subject,
including the fact that additional trials will be required to demonstrate the safety and efficacy
of the Company&#146;s HuCNS-SC cells for the treatment of any disease or disorder; uncertainties about
the Company&#146;s ability to continue to satisfy the lending obligations under the Silicon Valley Bank
loan and repay the loan when due; uncertainties regarding the Company&#146;s ability to obtain the
increased capital resources needed to continue its current and planned research and development
operations; and other factors that are described under the heading &#147;Risk Factors&#148; in the Company&#146;s
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2012, and in its subsequent reports on
Forms 10-Q and 8-K.</I>


<P align="left" style="font-size: 11pt">CONTACT:


<P align="left" style="font-size: 11pt">Rodney Young
<BR>
StemCells, Inc.
<BR>
Chief Financial Officer
<BR>
(510)&nbsp;456-4128


<P align="left" style="font-size: 11pt">Ian Stone
<BR>
Russo Partners
<BR>
(619)&nbsp;308-6541



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.2 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><img src="e38032-13100181121140395e_1.jpg">
</FONT>

<P align="center" style="font-size: 11pt"><FONT style="font-size: 10pt"><B>STEMCELLS, INC. ENTERS AGREEMENT TO RECEIVE $19.3 MILLION FROM CALIFORNIA INSTITUTE FOR<BR>
REGENERATIVE MEDICINE TO HELP FUND IND FOR ALZHEIMER&#146;S DISEASE</B></FONT>



<P align="center" style="font-size: 10pt"><FONT style="font-size: 11pt"></FONT>



<P align="left" style="font-size: 11pt"><B>NEWARK, CA (April&nbsp;11, 2013) </B>&#150; StemCells, Inc. (Nasdaq: STEM) today announced that it has entered
into an agreement with the California Institute for Regenerative Medicine (CIRM)&nbsp;under which CIRM
will provide approximately $19.3&nbsp;million to help fund preclinical development and IND-enabling
activities of the Company&#146;s proprietary HuCNS-SC&#174; product candidate (purified human neural stem
cells) for Alzheimer&#146;s disease. The funding, which will be in the form of a forgivable loan, was
awarded under CIRM&#146;s Disease Team Therapy Development Award program (RFA 10-05) in September&nbsp;2012.
The goal of the research will be to file an Investigational New Drug (IND)&nbsp;application with the
U.S. Food and Drug Administration within four years.


<P align="left" style="font-size: 11pt">&#147;With CIRM&#146;s support, we are now able to lay the groundwork that could result in the world&#146;s first
neural stem cell trial in Alzheimer&#146;s patients,&#148; commented Martin McGlynn, President and CEO of
StemCells, Inc. &#147;Currently, there are no good treatment options for Alzheimer&#146;s patients, and there
aren&#146;t any on the horizon, so it is clear that the field could benefit from creative approaches to
this devastating and challenging disease. Our collaborators at UC Irvine have provided a
compelling preclinical rationale to test the utility of our cells to restore memory in patients
afflicted with this deadly condition.&#148;


<P align="left" style="font-size: 11pt">StemCells, Inc. will evaluate its HuCNS-SC cells as a potential therapeutic in Alzheimer&#146;s disease
in collaboration with researchers at the University of California, Irvine (UCI)&nbsp;led by Frank
LaFerla, Ph.D., a world-renowned researcher in the field, and Matthew Blurton-Jones, Ph.D. Dr.
LaFerla is Director of the Institute for Memory Impairments and Neurological Disorders (UCI MIND),
and Chancellor&#146;s Professor, Neurobiology and Behavior. Dr.&nbsp;Blurton-Jones is Assistant Professor,
Neurobiology and Behavior, at UCI.


<P align="left" style="font-size: 11pt">In July&nbsp;2012, Dr.&nbsp;Blurton-Jones presented data at the <I>Alzheimer&#146;s Association Annual Meeting</I>
demonstrating that the Company&#146;s neural stem cells restored memory and significantly enhanced
synaptic function in two animal models relevant to Alzheimer&#146;s disease. Importantly, these results
did not require reduction in beta amyloid or tau that accumulates in the brains of patients with
Alzheimer&#146;s disease and account for the pathological hallmarks of the disease.


<P align="left" style="font-size: 11pt"><B>Terms and Conditions of the Loan</B>


<P align="left" style="font-size: 11pt">Loan funds are expected to be disbursed periodically over the four-year project period, with
disbursements subject to a number of preconditions, including the achievement of certain progress
milestones and compliance with certain financial covenants. The term of the loan is ten years, but
may be extended under certain circumstances. The loan is unsecured and will bear interest at the
one year LIBOR rate plus two percent; however, the interest rate will increase by one percent each
year after year five. The loan is forgivable, such that the Company&#146;s obligation to repay the loan
will be contingent upon the success of HuCNS-SC cells in Alzheimer&#146;s disease. No warrants will be
issued in connection with the loan, but the Company will owe various success milestone payments in
the event of the product&#146;s commercial success.


<P align="left" style="font-size: 11pt"><B>About Alzheimer&#146;s Disease</B>


<P align="left" style="font-size: 11pt">Alzheimer&#146;s disease is a progressive, fatal neurodegenerative disorder that results in loss of
memory and cognitive function. Today there is no cure or effective treatment option for patients
afflicted by Alzheimer&#146;s disease. According to the Alzheimer&#146;s Association, approximately 5.4
million Americans have Alzheimer&#146;s disease, including nearly half of people aged 85 and older.&nbsp;The
prevalence of Alzheimer&#146;s disease is expected to increase rapidly as a result of the country&#146;s
aging population.&nbsp;


<P align="left" style="font-size: 11pt"><B>About CIRM</B>


<P align="left" style="font-size: 11pt">CIRM was established in November&nbsp;2004 with the passage of Proposition 71, the California Stem Cell
Research and Cures Act. The statewide ballot measure, which provided $3&nbsp;billion in funding for
stem cell research at California universities and research institutions, was overwhelmingly
approved by voters, and called for the establishment of an entity to make grants and provide loans
for stem cell research, research facilities, and other vital research opportunities. A list of
grants and loans awarded to date may be seen here:
<U>http://www.cirm.ca.gov/for-researchers/researchfunding</FONT><FONT style="font-size: 9pt"></U>.
</FONT>

<P align="left" style="font-size: 9pt"><FONT style="font-size: 11pt"><B>About StemCells, Inc.</B>
</FONT>

<P align="left" style="font-size: 11pt">StemCells, Inc. is engaged in the research, development, and commercialization of cell-based
therapeutics and tools for use in stem cell-based research and drug discovery. The Company&#146;s lead
therapeutic product candidate, HuCNS-SC&#174; cells (purified human neural stem cells), is currently in
development as a potential treatment for a broad range of central nervous system disorders. &nbsp;In a
Phase&nbsp;I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and durable donor-derived
myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting
a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported
positive data for the first patient cohort. The Company is also conducting a Phase I/II clinical
trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in
Alzheimer&#146;s disease.&nbsp; StemCells also markets stem cell research products, including media and
reagents, under the SC Proven&#174; brand. Further information about StemCells is available at
<U>http://www.stemcellsinc.com</U>.


<P align="left" style="font-size: 11pt"><I>Apart from statements of historical fact, the text of this press release constitutes
forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the
Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein.
These statements include, but are not limited to, statements regarding; the potential of the
Company&#146;s HuCNS-SC cells to treat a broad range of central nervous system disorders such as
Alzheimer&#146;s disease; the prospect of initiating a clinical trial in Alzheimer&#146;s disease; the timing
and prospects for funding by the California Institute for Regenerative Medicine; and the future
business operations of the Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date hereof. Such statements reflect
management&#146;s current views and are based on certain assumptions that may or may not ultimately
prove valid. The Company&#146;s actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company is subject,
including the fact that additional trials will be required to demonstrate the safety and efficacy
of the Company&#146;s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to
whether the results of the Company&#146;s preclinical studies will be replicated in humans;
uncertainties about the prospect and timing of entering into the agreements necessary to receive
funding from CIRM and whether the Company will satisfy, and continue to satisfy, all preconditions
for such funding; uncertainties about the Company&#146;s ability to continue to satisfy the lending
obligations under both the Company&#146;s Silicon Valley Bank loan and the CIRM loan and repay these
loans when due; uncertainties regarding the Company&#146;s ability to obtain the increased capital
resources needed to continue its current and planned research and development operations;
uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in
the Company&#146;s cell-based programs will prove safe and clinically effective and not cause tumors or
other adverse side effects; and other factors that are described under the heading &#147;Risk Factors&#148;
in the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2012, and in its
subsequent reports on Forms 10-Q and 8-K.</I>


<P align="left" style="font-size: 11pt">CONTACT:


<P align="left" style="font-size: 11pt">Rodney Young
<BR>
StemCells, Inc.
<BR>
Chief Financial Officer
<BR>
(510)&nbsp;456-4128


<P align="left" style="font-size: 11pt">Ian Stone
<BR>
Russo Partners
<BR>
(619)&nbsp;308-6541



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>e38032-13100173129124a032_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e38032-13100173129124a032_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!4`:4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BB@\>I^
ME(#F@!:**3.#C!^O:@!:*/7KQ_GBB@`HHHH`****`"B@'/(HH`**0G&.#SZ=
MOK2T`%%%%`!1110`44F1G&>:,\XP?KVH`6BBB@`HHHH`3G/;'ZTCLJ*S.P50
M"69C@``9))[8%1W$\-M#-//*D,,,3RRS2,$CCCC4L[N[8551068D@``D\"OP
MR_;*_;CU7QO>:Q\+OA)J=UI7@FVDET[Q!XILI7M=0\5/&Q2\M-.N(F2XM/#[
MLK6\K(T<^K1"19<:?.T,_P`'X@>(61>'F3RS/-JGM*]7FIY?EM*4?K6/KI7Y
M*:=^2E"Z=:O).-*+O:4G&$O#S_/\#P]@GB\7)RG*\</AX->UQ%1*_+&_PQ6C
MG-Z13ZMI/[?^/'[?OPE^$DEYH'AG=\1O&=L[0R:;H]RD.AZ=,"5(U37C'/#Y
MD;9S::=!?W&]?+N/LBNLU?F3XZ_X*'_M&>+9IUT76M+\"6,A816OA[38);B.
M,X&UK_55OY7..CHD9#$LA7`QYW^SU^R9\3OVA;[[3H]K_P`(_P"#+>;;J7C7
M6(918-(,-):Z3!\LNLW^&#.D#+;6X(-W=0%XDE_9'X5_L"_`'X<16USJOAP?
M$/7HU7S-4\9!-2L0^!O^S^'6SHJ)N7>C75I>7$9X6X`.*_FW!XGQT\8I2QV`
MQO\`J7PQ6D_J]2G4JX&-2BFK>RJ4HO,,7-Q?\52I4)--*4=G^<4*O'/%[=>A
M6_L3*YO]W*,IT.>&UX2@GB:ST^).%-O1-(_#F;X^?M%>(KII8_BU\6;R?HT>
MD>+?$MJ@+`D?Z+I%Y;P`G:2,1#`4]@:DA^//[1GARY$\OQ7^+5I-E<#6/%?B
M:YB+<L`+;5[N>`E@"2IB.]1R&`K^G_3O#'AC2(([/2_#^BZ=;0#9#!9:586L
M$2J,!8XX((T0`<`*HXXZ5)=^'?#^HQ26]]HND7MO*I26&ZTZSN$D0@@JZ2PL
MK`],$$%?H*]U?1SXHY/:OQ3S98WXU-4,;R*IH_B_M55'KHIZ.VO+T.__`(A[
MFG+=\5X[VV_-R5W&ZMU^N7]'O;H^G\^/@7_@H=^T9X2FA76=;TOQW81$"2V\
M1:;!'<R(I7"B^TI;"56V`KO99&).]RS#YOTS^`_[?_PH^+<MKH'BD-\-O&$[
M1Q1V6LW<4V@ZG,YV)'I6N[8(_.D;'^B:C;V4H+!('O`CR#L/BA^PO^SY\3(K
MB:+PA;>"-<</Y6L^"4CT,>:V6+W6CVR+HEX7D.^:273Q=2DG_2D8[J_'G]H_
M]C+XC_L_R-KB,WC#P"TG[KQ1I=K*LNE,3^[A\062^:=/?D"*]226RG8?ZV"5
MA;CR,9+QV\(?^%'$X_\`UXX8P[3Q/M*E7&SI4$]9575C_:&%=MZD9UZ$':\F
MCDK/CKA%?6*E=9[E=/6KSRG6G"FK)N3FOK%)I:\T95*<;:MK?^@/XD?%WX>?
M"70&\2>//$^FZ'IAC9[42RF6\U%@H80Z;90"2ZOIFR-J6T4GWE+;00:_)[XL
M?\%0?$5]<76G_!_PC:Z/IZ,R6_B+Q9_IFIW*@L!-'HMI*MG8JV%VQSWM])M^
M9O*<F)?S*%WX^^)6J^'_``^;SQ1XWU>*"WT+PWI<]YJ.N75O:(Q%MINEP3R7
M#6UK$SL5@MQ'!$,L0J@D?JE\"_\`@F6)[6Q\0?'/6IHY)XH[@^"/#EP(WMPX
MW_9=6UQ0Q,Z@A+B+2UV(P=(K^7B08R\4/%?Q;Q<LN\.LL?#V54E".,S*4X.=
M*4E'G=;,:E/V=*SYN2CA:4L0X)/63L9OB?BKBVL\-PYAO[.PL%%5L7)IRBVE
MS*>(E'EAK?EA2@ZKCKNSX1\3?M@?M)^+))&OOBQXHL(Y"0EKX=N(_#\,2M_#
M$VCPVMUU)*L\\D@XP_%<J/BU^T@T)N/^%F_&\P8R9_\`A-/';0@`A=WFC4PF
M`?ESG`)P3UK^DCP+\!/@U\-K6"V\&?#CPIHQAC""]72+6[U>8`$9N]9ODN=6
MO7P3\]W>S,`2H(7BO3/[+TK;M&G6&SGY/L=OM/MM\O'7V]Z]JC]'KC3'1^L9
MYXHYF\=-?O(T%C\53A-I.T:]?'T)3BM5_!IZ)6MLNZGP#G=9*IC>*L9[>6LE
M!XFK!2TVG/$TW)?]N1TMIV_F<\*_M??M)>%)8_LGQ7\47J0N%DM/$4Z>($DV
MX!BG?6(KJ[!RI#%;B.3(;+9+9^X?A/\`\%+O$<$MM8?%CPC;:S9-M6;7?"96
MRU.($@>:VDWLWV&\]TAO=/*@[@TA&T_J'XR^"WPF^(%M):>,OA]X3UQ9(VC\
M^ZT6Q6^A5NIL]3AABU"RD]);2ZAE7G#BOS[^+_\`P3>T66*[UCX*ZO-I-V@D
MFB\)>(+N6[TV<@EUMK#69F>]M'(^2$ZBUXA8*LUPBNTL>=3P\\;>`D\;PQQG
M7XGP=#6678BI5E5E!=(8#'U,31E&WV:&*C5DW:,'N1/A_C7(G[;*\YJ9I1AK
M+#U93E.25OAH8B=6#VU4*L92>BCWYKQK_P`%#?%NNW4UK\.?#5GX;TSS-L&I
M:\RZGK$\6?EE>TA>/3[%F7K");_8P)^T/G`\XB_:`^,WB>96U'X@>(1YN[;#
MIER-*1=X("(-+2U<XSA-SNX/W6)&:^B_@O\`\$^=+TNVL]5^+NKOJFH,D<S^
M&=!N9+?3;9B%/V:\U95CO;QD'RR_8A91A\K%/-&HEE^_/"_PS\`>#+:.T\,>
M$/#^CQQJ$+VFF6HN90!@-<WLD;WEU+@#,US/-*V,%R`,?0Y-P9XM<4\N8\5\
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M^15\/:Q<:G`IN4C\S:"6CRN>,\J21D^Q'TKI:R-.T>#3&/V9G\HC`C<EBO7A
M6/)&,#G)XZUKU^AX=58THJL^:HDDY=]%KT>]]]>Y]!34U%*;O);OOIY!1116
MQ84444`%%%%`!129`ZG%`8'H1S[T`+13=P'4X-%`'A?[2'[1_P`)_P!E'X1>
M*OC;\:?$D/AGP/X4MXVGG""YU+5M1NG\G3-!T'3E99M4US5K@BWT^P@^:1R\
MLC16\,\T7\>?[2W_``<P_M+>+]9U/3/V8_A]X%^$?@])Y8M-\2>,M,;QUX_N
MK=)"(+IH+B\@\'Z2TR\S64VB:^5R@CO4(<-L?\'./QW\3:]^T'\'?V>H-3O(
M/!/@'P$/']]HL<TB66H^,?%M]?6,.K7<"[([B?3-!L$L=->42M9K?ZKY+H+^
M=6X/_@@A_P`$SO@5^V)/\4?CC^T+IQ\<^$_A=K^D^$O#7PR.H2VFCZGXBO[%
M-:N==\6)830W^H:?969@MM-T5Y[;3[R:>[FU**_@BA@7^F>"^#.#.&N`X>(?
M&N"EG#Q*C6P>`<?:T84ZM?ZOA:4<.YPHUJV(FN><\0W2IPDO=7*V_P"?.+.+
M.*<_XR?!/"N+661H3E2Q&+C/V=6I.G25;$5'6474ITJ47RQC22G.47[S32/D
M;3/^"^'_``51T_4([R[_`&D=/UJV1V9M)U3X+_`N'3Y@S`A'ET;X;Z1J@1>5
M!BU.-^?F<GD?T(_\$=/^"QG[1W[>'QDU;X&_&'X6>`/^)!X$U/QC?_$[P(NM
M:!':KIMWING6=EJWAK4]0U^VEO=:N+\LMSI^I:?;*UO<-%IL42K&OZI:S_P2
MS_X)YZ]I+:+J/[(WP5%FT7DJ;+PE9Z;=PJ(C"KVU_8?9KVWF2-B$GAG25"=R
MN&P:H_L??\$S/V8OV&/B'\4OB!^S[I/B;0G^*NGZ'I=]X=UO7W\1:1X9L=&N
M;R[:T\+W>HVS^((;/4;FZCGO(-8UK63'+;0K9RVUOF`?.<2\<>%V>\/YGAL!
MP)3R3._9*.5XC#X;"4*2J2J4XRJ5*N!E0ES4X.4XTZM&K2FXVDTW8]SA_@_Q
M#R?.LOKXSBZIF>5*KS9A1JXG$UIRIJ$FZ<*>+C524Y)1<Z=2$XWNE9:?47[2
M'Q5N_@5^SU\=_C=8Z/;^(KSX._!KXG?%*T\/7=W)I]KKMU\/_!6M^*[?1[G4
M(8+J:Q@U.724LIKN*VN)+:.9ID@E9!&W\F__`!%._$[_`*,\\!_^'=\0?_,/
M7]<_QE^%V@_'#X0_%/X+^*KW5].\+_%WX<^-_ACXDO\`P_/96NO66@^/?#6I
M^%M7O-$NM2L-5T^VU>VT_5;B;39[_2]2LXKQ(9+JPO(%>WD_`K_B&$_81_Z+
M!^UO_P"%Q\&__G#?E^N:^:\/L=X9X3"YC'CW*L9F&)GB*$LNGA7B[4Z"A)5X
MS^K8S"QNZG*US*;M>S2N>_QQ@_$#$XK`/@W'T<'AHX>JL;&K]6]^NZB]DX^W
MP]9V5.Z?*XKNGNO@W_B*=^)W_1GG@/\`\.[X@_\`F'H_XBG?B=_T9YX#_P##
MN^(/_F'KG/\`@J=_P1`_96_8=_8]\7_M!_"OXB?M!>(O&7A_Q5X$T.RTOX@^
M*/ASJGAF6U\4>)+/1K^2ZL_#GPJ\*ZJ\\-M</)9M%K,,<<X5IXKB,&,_C3_P
M3"_92^'W[:_[9GPT_9U^*.M^,O#W@OQGI7CZ_P!2U7P!?Z)I?BBWE\*^!/$'
MBC3TL;SQ%X>\4Z5''-?Z3;PWHN-%N6DM'FCA:WF9)X_WK)^&?!3.^&<TXLP7
M#6*_LK*/K?UMU<3FT,1_L6&HXJLJ=+^TY*;]E5AR^_'FDY+0_&,SX@\6,IS_
M``'#>+SV"S+,?JOU=4Z67SI?[76E0I>TJ?4UR>_!\VCLK/J?MS_Q%._$_P#Z
M,\\!_P#AW/$'_P`P]?KO_P`$EO\`@K5XJ_X*4>*_C1X;\1_!7P_\*8_A5X>\
M'ZW:W6B^,M1\4OK+^*-2URPEM[B*^T'1ELUM%TA9$DC><S&=E94"`M\]?\0P
MO["&?^2P_M;Y]/\`A.?@W_\`.&S_`#X_.OT(_8!_X)4?L_?\$YM>^)/B+X+>
M-/C'XKO?BCI'AW1=?C^*.O>"=9M;.U\,WNIWUC)I">$_A]X*E@GFFU:Y6[:]
MGOXWC2!88H'61Y?R/BW,_!?$</YA1X5R/,<)GTXX?ZAB*\L?[*FUB<.Z_.J^
M8UZ;YL,JT5S4I>]+3EEJOTSAG+_%BCG>!J\19KA\1D\95/KM&G]2YYQ="HJ5
MO986G4TK.FWRS3T=[J]_TUX`_P`/SK\$O^"BO_!>+X+_`+%OQ`U+X*_#;P:W
MQX^+OAY8D\96UKKHT'P3X+U&9%F7P_JWB&*SU*>_\0P6[QRZE8:39W$6DO/'
M8WUW'JD5]I]E^WOQ$UUO"_P_\<^)4=XW\/>$/$FN)(B[WC?2=&O+]'5,C>R-
M`&"Y&XC&>:_RD;"V\9_'KXOV%CY[ZS\0?C)\1K*PBFNI6+ZEXM\?>(X;2`S3
M2%F`N=5U5`6);8C=]HS'@SP#DW&&,SC,.(>>IE.1T:$ZF&C4J4(XBMB/;33J
MUJ3C45&A3P\YSC3G"3<H>\E=/;Q6XSS7AC#99@LDY:>8YM5JJ.(E3C5E2IT7
M1C:E3FG"52I.M&,7.,HQ49^ZVTU_3?\`\13OQ._Z,\\!_P#AW?$'_P`P]'_$
M4[\3O^C//`?_`(=WQ!_\P]?4/@G_`(-=_P!GB/POHP^(G[17QIU#QD;*W;7K
MCP;:^!M%\-?;WB1KF+2;#6O"_B+4UM89B\<,UWJ3RSQA97A@9C&.I_XA>_V1
M/^B^_M(9ZX%Y\,?US\/.G]:^SGF'T<(3E!93BYJ,G'GA_K"X2LTN:+>+3<7:
MZ;2NF^[M\G#`>.TX0G_:5&//&,N64\H4H\R3Y9)89I25[.S:33UT/9_^"5?_
M``6C\8_\%%_VAO&'P1\0_`7PU\+K+PQ\&_$/Q2B\0:-XZU3Q/=7=SH?C7X>^
M$TT>2POO#FD10P7$7C::]:[6Y>2.33XH1`RSO)'^_P#7X_\`_!/_`/X(U_`G
M_@GE\9?$GQJ^&/Q.^+7C3Q!XF^&FL_"^[TKQY<>#Y='@T?6_%'@WQ5<:A;+X
M?\*Z'>#4HKSP786\+2W<EK]ENKP/;O*89(OV`K\/XXK<*5^(*]3@RA4PV1/#
MX54:57ZUSJNJ26);^N5*E?WJMVKRM_*DM#]@X.I<24<DI0XKK1KYPL1B'4J0
M=!IT'.]!7PT(4KJ&CM&_=L8.-QQCOWYZ_P">*_C_`/VM?^#D+XU?"[]HWXG?
M#+X,?!3X7WWP_P#AIX[U_P`$+JWCB[\3:CX@\6/X6U:?2-2U>!]#UC2-/T2U
MU&YL[EM-MVM]6E@M6MYKF224R6Z?UL>.O$47A#P7XN\63NJ0>&?#.NZ_,SX"
MB/2-,NK]RQ*M@8@Y^5O]UNA_R:O&_B"3Q9XT\7>*9I9)Y?$GB?7]=DFE8M)*
M^K:K=WYD=F"EG<S[F)522>0.E?IW@3P5D?%>,S^OGV`AF&&P&&PE/#TJDZT(
M1KXFI5E*I^YG3;E&G1M&\G;G;23LU^>^,?%F;\.8?)J&38V>"KXRMB*M>I3C
M3E-T:$:<81]^$[1E.;<K+7EM>VC_`-/?]@G]KSPY^W)^R_\`#S]HC0=+A\/7
M?B8:QI7BOPG'?IJ,WA/Q=X;U2ZTC6='GG"1.Z3&WM]8TQIX89Y]$U72[N2)/
MM(%?9&3SQVX_+O\`C7\?O_!KW^T"8+O]HC]E_4[K]Q?/I/QG\)6TDB@1WRV]
MKX1\8K!&3O=KNTM/"DTFT;(A8,V-TY-?V`KG&#VX_*OS;Q"X;CPIQ?G.2T8R
MCA*.(5;`J3<O]BQ4(U\/%2E[T_91FZ#E)MN5)MMNY]]P-GT^).%\KS2M-3Q5
M2BZ.,:27^UX=NG6;BM(NHTJO*DDE45DE8^6/VT_VI/#W[&O[-'Q._:'\1Z6V
MNQ>!-(BDTGPZMVM@_B+Q%J=W;Z9H>C+>.DHMDN[^ZB-Q.(I9(K2*XDCBED1(
MW_F(_9Y_X.5OCAXZ^/WP\\&?%7X(?"G3OAEXZ\<:#X1N[KPK>>*[;Q-X8M_$
MNLV>D6VKOJ.IZKJ6G:M'I)NUN+VW_L;3S=PQR-#);N%C?V[_`(.?/VCX]#^&
MWP'_`&6M%U%/[4\=ZYJ?Q7\<644I$]OX6\)C^P_"$-W#G#6FO>([_7+NW8@D
M7'@V0`JI(?\`C3L;Z[TR^LM2L)GM[[3[NVOK*X3A[>[M)DN+:="00'BFC212
M00&49K]W\)_"S(,\X'Q.<9[EJQ>.S6>-66U)U:U.6'P]"+P]&=*,)P2G/%0J
MS4IQES)0WB?C/B1XB9UE7%]#+<HS"6&PF6K"?7:<(4I1KUJKC5K1J.<)-PC1
ME"*2:2;G?5:?Z[BN'`*YVD9!['/3%&"&_P!D\_I_C7FGP8\?V/Q6^#WPI^*&
MDM#)IOQ(^''@CQ[I[02"6!K#Q?X:TWQ!:-#('<21&#4(S'()'#H0P=L[CZ+>
M745E:W-Y.XC@M8);B:1CA8XH8VED=CV544L3Z"OY7Q,'A:E>G6]QX:=6%6_V
M71E*,[^G*S^C:%:-;#TL0G:%6C"LGTY9P4T_N?\`P#\OO^"CO[15]X+\/67P
M9\)Z@UGKGC&S-]XIO+60I=67A;S7C33XW0AX7UR:&6&=U(+Z=!=6^-MTQ7X`
M_8V_9@N/VA?&LEYK@N+;X<>$[BUG\27$1:.36+AF\^#P]:SC:8VO(T)U":)A
M-:V;9C*3S0.OBGQL\>:I\7_C'XT\7RO)<S>(_$\]MHT#,7^SZ5#<#3-`TZ(@
M!2+>PAM(2RA?,D\R=EWR,3_1_P#LY?"?3O@O\(/"'@NTM4AOX--AU'Q%<*FR
M:_\`$>H(D^K75QGYV<3L+>,.6\BUMX+=#Y<2BOXDX<R^7CCXMYOG>;N5?A/A
M:HJ>%P<VW1K4Z5><,%AN57CRXJI3JXO$VLZD%R7Y79?CN7X=\;\68S&XN\\H
MRJ7)1H2UISC";C1I6V2JRA*M5>\DN7;;T<#P9\,O!\KO-H/@KP3X1TB:YN;N
MZGLM$\/Z!HNF0--<WE[=W+V]CI]A:6\<DUU=W,L<,,:R33R@!FK^7+]N/_@Y
M&T3PCK6N_#[]B?P=HWCFZTZ>XTZ7XS^/(;]_",T\,CP3W/A#PI:W&F:AK=LC
MHS6.KZM?66GW>8KN'3[ZR*BX^9?^#@?_`(*5ZUX^^(>J?L1?![7+C3_A[\/[
MB.+XVZOIMTT?_":>-L)./!1:!@6\/>$D,7]JQ2,1J7B*6:WFA2#1HWO?S:_X
M)E_\$HOB[_P4.\27FMB\O/AM\`_"VJ1Z?XM^*=SI;WAU+48Q!<7GA/P-;7#P
M6VL>(X[*:&6^G:1]-\/QWEG<:B)I+BVL;K_6GP_\+N&,BX9I<:>(+I8?+%1I
M5,MRB?-2H4\-HL/*M1I)5*]6O&WU?!4E94^5SC-RY8?NV'PM*C2C.HHQA&,5
M""248Q5N5**MT2LEHEIL>8_$#_@K/_P4<^(^KS:QKG[7OQ@T>665I$LO`6O1
M?#32+=29"D$.E>`+7PW9>5$LA1?.BFED"1O/)-*@DJW\-_\`@KG_`,%'_A?J
MT6K:%^UM\5=?*S)+-I_Q&U2U^)^DW2*1NMY;'Q_9^(4AAE4;':Q:SN%!WPSP
MS`2#^W#X)_\`!&3_`()V?!+P[9:+9?L^^'/B)J=O;I#?>+_BNS>.?$VK3A`D
MUY<R7RPZ/I\EQC=):Z#H^CZ<A.(;*,<5/\9O^"-7_!.SXT>';S1-0_9W\+>`
M[^>W:*S\6?"WS/`WB;2IMI6&[MKG3,Z;>/;D[TM=:TO5=.D(VW%E,A*UZS\6
M_"CVRP7_`!#^D\LO[+ZP\KRCF]GI'G^JVYN7=V]MSJ.JCS>X]/K6'O;V?NZ:
M\L>C73M_EL?E;^PE_P`''?A#XCZ[HGPX_;0\)Z)\+=:U:>VTZQ^+?@I-1;X?
M2:A</'!$WBO0]1N]3U7PI:S2-F;5K?4-6TVU8B2[2PLA+/;_`-/C#0_%VB#!
MTWQ!X<U[3@ZNC6VHZ7JNF7\.Y)(Y$,MM=V=W;R*R.C/%-$X96*MFOX5OCI_P
M;M_M8^#OVA_#GPW^"UY9?$SX.^-+J\N=/^,&L"WT&W\!Z3:21-<6WQ%T^.>=
MTU6WBG2/3WT-+F/Q*Z//96FG[;NTL/[#/V'?V5H/V,?V;O`/P`A^(OB_XH'P
MA;W4EQXG\87*22"\U*5;J]TOPWIZ`C0/!^GW1EC\.Z`UQ?RZ;:.4GU"\G>29
MOSCQ3RCPVCA\NS/@O,:53^UH2>*R*$:E>A3P\HS4JTO;7E@I*:]E/!5^9RNY
M4XPA%\W/BJ>'<;P<6IK6G\47%K5.+NEYIZ;Z'0?!G]E/X4?`[Q%XI\3>$-*D
MDU7Q%J,UQ9W.H[+E_#>E3JC-H.B2,H:&P2?S9/,<M=RPO#;3SRI;(S)^U-^U
MY\!/V-?AM=_%'X^>.;+PIH2/]DTC3(HWU'Q3XKU9E)AT;PKX=M2VH:O?R$`R
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M6/V__:;_`.#F/XZ>*;W4=$_97^%_A/X7^']T\%GXT^(5N?&OC>6+(6&]L]#2
MXM?"6CSC:7,.I6WBF%ED"-&K)N/Y@ZM_P6?_`."G6LZHNK7?[6OC.WND='2#
M2O#/PVT33`8Y6E4'1M'\%V.E2IN8JZ364BRQ@12AXP%K]O\`_@GM_P`&Z'A6
M\\,Z%\5/VZ[[7+[5M9L[74M-^`7AO4+OPW:Z);W$2SQQ_$/Q-8RPZ]=:N5D7
MSO#OA^;0UTB>!H[_`%?4VFFL+3]O;;_@D9_P3=L](.CQ_LB_"62W,?E?:KG1
M[B[U;&T#<-8N+N35!)QGS!=A]Q+;LL2?V3$\:>"G"-:6593PC3S_`.KS5*OF
M,L)A,7"<HM1J.&,S&<JV(::;_=1AAY2UIRY7<]'VN%I/EC!2MNTKZWVN^UNA
M_+/^R=_P<`?\%$[?QWX,^'?BW1O!O[4TWBK7=*\-:5HFH^$]-\'>/=1O=2N8
M+#3[+2=>\!6NAZ(LSR2+Y]WK?A;5'=0T]W>1!9K@_P!T6DS:C=:5IEUJEE'I
MVJ7&GV<VI:=#<_:X;"_FMXY+RSBO!%;_`&J.UN"\$=SY$/GI&)?*CW[!^8WP
M,_X(Z?L/_LX_M&Z;^TK\)/`>N:!XGT71-5T[0_"5_P");OQ#X$T'5]5DME?Q
M=HFFZ['?ZU8>([:P2]TNTVZ])HUI::E<RVFD6]\D%W'^I8Q@8Z=OI7X]XBY]
MP?GV88.OP?D$<DP\<,Y8U^QAA95\34:_=_5:%6IA:<*$8Z5*23JRJ2<G:*OR
M5YTIR3IPY=/>=K7?IMI_PQR_CGQ#)X1\%>+_`!7#;)>R^&/"^O\`B&.SDD,,
M=W)HNE7>HI:O,J2-$EPUL(FE6-S&'+A&(P?Y&?#G_!T%\2M<\0:#HLG[(W@B
MW36=9TO2WG3XL:[(\"ZC?06C3*A\$J':(3%PA90Q7!(SFOZP_C3_`,D<^+'_
M`&37QU_ZC&J5_E/_``__`.1Z\#_]C=X9_P#3U8U]UX*<%\-<68'BRMG^6K'U
M,MA@7@I/$XNA[%UJ.83J:8:O14^:5"D_WG-;ELK)ROMA*5.HJCG%2LXVW6Z?
M9KL?ZU2DE03U(S3J:GW%_P!U?Y"G5^`'$%(QPI/H"?R%+37^XW^ZW\C36Z]4
M-;KU1_'!<_\`!TC\3()[B$?L@^!V$,TL88_%K7@6$;LH)'_"$'!.,^U?V%Z!
MJ)UC0]&U=XA`^JZ5IVI/"KEUA:^LX;IHE<A2XC,I0,54L!DJ,XK_`"1]1_X_
M;[_KZN?_`$:]?ZTW@C_D2_"'_8KZ!_Z:;2OWSQMX,X;X2H<)SR#+E@)9E2S*
M6-:Q.+Q'MGAX98Z+_P!IKUN3E=>J_<Y;\_O7LK=F*I0IQIN$>5RO?5ZZ+NSJ
M****_`CB"OR0_P""H'_!6+X7?\$\/#^D>'+?3(?B/\>_&6FW&I^%?AQ#>O:6
MFDZ,CRVL7BOQIJ$$<LFEZ+-?Q26NF6<8&I:Y-:WRV2I;V-Y=P?K<WW3]/\__
M`%J_S$_^"F7Q<U_XU?MW?M/>,-?OKB\DL?BQXL\$Z4DS,4T_0_`6JW/A'2]/
MM48GR[:WAT@LB`[2\CN/OFOUKP>X'P/&W$E6CFO/+*\KPJQN*H4Y2A+%3G45
M*AAW.-I0I2ES3J2@XS:@HIKF;73AJ2JS?-\,4G;NV]/U/<?C5_P6R_X*0?&C
M6[S4)/VA-:^%^CW#SBQ\*?!RQT_P%I6DV\QS]GMM6LH9_&5\4!"I<ZSXGU.[
MCQF*>(':/,?!/_!67_@H]X`OH=0T3]L'XQZA-#)Y@A\:Z[;?$6QD)()2;3_'
M]CXELYHVVX"/`0@+>5L+$G^L#_@BY_P3B_9:\-_L??"+X[^+/AGX,^*'Q7^,
M&@S>,-6\5>,]&L/%$>B65[?75M8>&=!L-7M[G3]/M;"ULXA?-#:"YNM1:Y:X
MFE6.$)^JGQ'_`&#?V-/BUHTNA>._V9_@UJNGRQ-$!:>!-`T.[@W`_O+74=!L
MM-OK6=228YX+A)8V^9'5@#7Z9F7B?X:9+F6*R*AX<X'%9?E^(JX&>*6%RV$Z
MDJ$W1K3AAZV%E.HN>,N6=;$1J5%:4E%R9T/$4(/D]E=)VO:-M#XN_P"",W[:
M?[17[</[-7B3XH?'S2/!T6H^'_'MQX(\/^)O"FDW>@KXM@TO2;"\U6_U72WN
M[W38-1M;K4(()'T865A('^33K0IABOT*_9H_9J^$W[)/PET?X)_!31;S0?`.
MA:KXEUC3K#4-2NM:OH[GQ1KVH:_>)<:K>E[V^2TEOQINGRWLMQ>1Z38V%M<W
M5U-`]S*5_.O$.-RS'YYFF,R?`1R_*\1C:U7`X)1Y%A\,Y+V=/DC*48.RNX0;
MA%R<8VBDCBG*#FW&"46[I;66FEEIT_K6_P#+]_P<Q_L?>.-3UKX9?MC^#]%N
MM8\'Z5X:7X:?%:>PA,LWA>X@U66]\(>(=12/,@T?5?[2O-$FO-I@T^_M-/CN
M'7^U(37X;?\`!.3_`(*8?&3_`()T?$'5M;\$Z=IOC;X;^-I=.7XC?#37)Y[2
MTUN+3BZ6^J:'JUNLLN@>)K.WFFBM=2^S7UI/$PM]2TZ\A2+R?]*OQ)X;\/\`
MC#0=8\*^*M&TWQ%X<\0:;=Z3K>AZS96^HZ5JVEWT+VUY8:A9722V]U:W,,CQ
M30S1LCHQ!%?S%?MF_P#!M5\,?B!=ZWXV_8]^(,/P@U^Y:>]A^%OC>#4-;^'-
MS<2$O]ATCQ':/<^)?"-MN.8O/T_Q9;H%6W2VMD9KB/\`=?#OQ-X7J\,1X#X]
MPZ>60C+#X7&RISJX9X>=1U:=+$JBG7H5:%63='$TTU%*$G*FX<S_`)^XX\/N
M(*7$,N,.#JS^O2DJ]?"QG&&(A6453J5,/SVIUJ=6"2J4)M<WO64N:R_1K]D[
M_@MK^PK^U2VD:)#\0C\'/B#JA@MQX&^+OV/PS+)J$YCC6RTSQ+]KG\+:J\DS
MB.U$6J17-SNC46D<SF%?UT1XY426-TDCD57CD1@Z.C@,KHRDAE92"&!((((.
M*_RS?VK?V&_VF_V+/$UOX9_:$^&FI>$TU"::+0O%%I-;ZYX+\2^2"Y;0O$^F
MO-IUW)Y.V=[&9[75+>-MMY8V\J2Q)^Z'_!"/_@J[\2/"_P`7O`W[&/Q]\:ZA
MXM^%_C]X_"?P>U_Q1?2:AJO@+QE(@'AGP;'JMWYM]<>%_$<R#0-#L+BXF&BZ
MO<Z38:>D6ES^599\:^"V74LEK\5<"9K_`&MEE*E/%U<%*M3Q;^K07-4G@<71
MTK>QBI.5&K'VKBFE4E-<LM>%/%C'RS6CP[QCE_U#,*E2&'IXJ-.6'M7G[L(X
MK#U/X?M):*I3?)>2]U1U7]LM%`.?_K<T5_.7<_=ULNA^('_!PU_RC'^)G_90
M_A!_ZG>EU_+E_P`$`?\`E*1\!^Y_X1WXR\?]T@\:5_4;_P`'#7_*,?XF?]E#
M^$'_`*G>EU_+E_P0!_Y2D_`;_L7?C+_ZJ#QI7]4>''_)B^/?\7$7_JFP)_-W
M'O\`R>'A#_%D/_JSKG^B41@[@,GZ_K_2G445_*Y_21Y-\=\?\*2^,9Y_Y);X
M_P`],?\`(IZL?PZ5_ET_LJ:[HWA;]J#]FSQ/XBU*ST7P_P"'/CW\'M=UW6-0
ME6WL-*T;2?B%X=O]3U*]N'.V"TL;*WGNKF9CB.&%W/`-?ZC/QW_Y(A\8O^R6
M^/\`_P!135J_RD_`_@[Q!\1/&7@_X?\`A.S34?%7CKQ/X?\`!WAG3Y+JVL8[
M[Q!XGU6TT71K.2]O9;>RLTN=1O;:%[J\G@M;=7,MQ-'$CN/ZI^CM2I5\GXWH
MUZBHT:JP5.K5;25*G/#8Z,ZC<FHKDBW*[=M-=#^<?'*I4I9KPC5HT_:U:<L7
M.G32NZDXU\"XP26K<I62MKKY'^FPO_!37]@#`'_#7'P.X4`_\5QI><@#MYG^
M>E._X>:?\$_^O_#7'P/^O_";Z7T_[^5_$P/^"`G_``5*(!'P"T#!Y'_%YO@Y
MW_[GBC_AP'_P5*[?`+0#_P!UF^#G_P`W%>+/PO\`"=1DX^*>";2;4?KF4.[2
MNEI6OKHN^OH>G#Q#\2&X1_XA]BU&\8N7U7,=%HF_X/9W\N^C/]$X$'D="`1]
M#2TR,%8XU/4(H/U"@&GU_.+W?J?O,6W&+DK-Q3:[-K5?)GPQ_P`%+OB&OPL_
M8'_:T\;"Z^R76G_!3QEIVF3DA0-:\2V)\,:'&29(_P#6ZOK%E"`K"0^9B-7D
M*1M_G>?L+?LQ7G[7O[1.B_`ZR:>%]=\"?&#6X[R`L#8ZGX4^%/C'Q%X7GEV1
M2L]O+XQL/#UE-$$_?1W9A)7S-R_VD_\`!QC\3/\`A!?^"<&O^%(YA'-\8OBS
M\,O`!0%Q*UII6IW?Q0N638K83=\.X()F=HXREQY+.6F2*7\-O^#9?X?)K_[9
MWQ1^(,T'FQ?#SX(:G8V[E`T=MJ'C7Q%HEI%.'W*4F-AI&I6R#:X:*XGSM.,_
MU%X6XJOPMX2\9\4T6J>*EBZKP525FO:X:CAZ%%-.RE_M-9W5VFM%K='\Z^(V
M'AQ%XD\,\/U+RP\:%*&(BND,34JU:DO\2IPT[6W1^;'_``2]^/\`=_LB?\%`
M?@9XW\13R:'H:>.V^%GQ-BN28DLO#/C:=O!^NS:B"R%8?#6H75GXBN%SD2:$
MHVR`&-_],X2*<$=",YXQC&<YS7^:[_P6'_9XN/V8?^"A?QQ\-Z?9/IWA?QGK
M-C\8O`$T<)@AFT#Q]&=6NA8J>##HOB^+Q-X=5U.'ET5W.TL0/[)?AS^W]8V7
M_!'K3_VUKBXM;WQ'X3_9YO%^S74_[K4?BWX8M)O`FGZ1>ROND8:EX^M;*WOI
M56240W,]Q'#)M"-Q^-&5KB;#\"<897#VDN(L+A,KJ<JO?$8F,*^"C-QNE+FJ
MXFDUNG3:^RSI\*<R_P!7JW&'#68S<5DE7$YA3YG_`,N<.Y4<2X1>O*U3HR3Z
M\Z>S/XXO^"S?[00_:(_X*%_'/7K*]:_\.^`-3MOA%X899C-;PZ?X`$VFZDMK
MD`113^)I->O)$4E3=7%Q("QD)KYM_;._98U[]D+XF>$/A=XG2\B\0:K\&OA7
M\0M>@O$"2:?K_CCPQ;:UKFB8!(SH&IS7&BRX`S-8R'YB2Q]8_P""97P/U']K
M3_@H#\"_"/B*.7Q#8WOQ%7XF_$:>]_TG^TM&\)7;^,M??4]P`GBUN\M(["_W
M%3*NI2\DG!_6/_@Z`^'3:'^TO^SQ\3(H5CL_'WP>UOPRTBJ1Y^J_#WQ4;B\8
MML"L4TSQMH<>W>S*J*65`R%_V?!YW1X:XIX)\.<*XJC'AO$O$K1OV^'H4OJC
M>VK6%QM25M6YIM:MK\KQ655<^X=XLXXKJ3J2SS#JC)\UO9UJLGB+?X95\/"S
MM9+331_T:_\`!&?X@O\`$;_@FG^RKJ4\IEN_#?@&3X?7(+F1H4^'^N:KX3TV
M(NP!P-%TK2W5.D2NL0)"9K[>_:`UZ3PS\$OBKKD!99=,\">);E&7J&&E7(!7
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M/V/PAX7U/Q!<_O)!Y<?[G3G^>3]VA^9_E!K^??\`8.GBM_VKOA'),X1&N?%T
M08_\]+CX?^*X84^KRR)&/5F%?M'^WOI=]KG[#7[9&CZ7$]QJ6J_LL_M`:?86
M\13?<WEY\)_%D%O;*7P@-Q*Z0Y)``?.Y>H_EGZ(^#PU3AO,*LU%5,9Q?3PN)
M>TGAZ>&R[DYFO?LOK->SZ-R:U/(\*J=-Y1BZME[2IFLJ<VMW&%##..N]KU:E
MK[7=MV?YDD2^-?CU\7H(BTFM_$+XQ_$6WMDY;?J?B[Q]XCCMX8TWF1U%SJVJ
MI%$K%RBLJ_-MK_43_9A_9_\`!O[+OP'^&GP,\"6<%OH?@#PQI^D/<0Q)`^LZ
MOY2S:[X@O`JC=>ZYJ\EYJ=R[9;?<[,X50/\`,Z_8N\3Z-X)_;&_9,\9^([M;
M#P]X0_:8^!'B?7KYRH2RT;0?BCX6U35+MBS(NVWLK6>9MSJN$.6`YK_4_0Y1
M3URH_E7^F7TC\9B:57A7)Z<94<LA@L3BH0@VJ52O3='#PAR))7PM&RAJ[+$/
M1=?UO&MKV<>GO/UMRVOZ:CJ***_F$\\****`/YJO^#F;XR:AX2_93^%7P?TV
M\:"/XM?%%-0\06\4I1[S0_`.G_VO;6UP@D4RV;:_>Z7>E&1T^V:;9RDJ\*$_
MSG?\$;+3]GRU_;C\`>/_`-I3QQX+\#^`?A/IVJ_$+2KGQSJ5KI^D:EX[TG[-
M#X.@S>8BFGTW4[LZ_;(<M'>:1:3!&"$#]KO^#I'2K]M#_9,UL>=_9<>L?$?2
MW^6/[/\`;YK'0+N/+;?-\[[/!+M4-Y>S<2N[!'\HGPT^$7Q/^,VNS^&?A1X"
M\4_$/Q#:V,NIW&B^$='N];U*'3H9(XIKQ[2RCEE6WCDEB1Y2NQ6=02,BO[:\
M*<HPF+\'IX-X]Y7#-WF\<=F-.5.%3#.IB)X:4U.HXPC*.'IP2E.2Y4[IKIZV
M'2^KVORWOKVOUZ'^E9_P\Q_8"SC_`(:V^!O'/_(\:9C\/FZTO_#S']@/_H[?
MX&_^%QIG_P`77^>1_P`,!_MM?]&K?'/_`,-YX@_^1*/^&`_VVO\`HU;XY_\`
MAO/$'_R)7Q__`!`S@/\`Z+]_^#<J\O\`I]_5_2V7U2E_S\_+R\^OZ^A_J`^&
M?$V@>,_#7A_QCX5U:RU_POXJT32O$GAS7=,G6YTW6M!URP@U/2-6T^Y3Y+BR
MU'3[JWO+2=?EE@FCD'#5M@YY%?,/[$6@ZWX5_8Q_9'\+^)=+OM#\1>&_V9/@
M-H.O:+J=O)::EI&M:/\`"SPKI^J:7J%I*JRVM]I]];SVEW;RJLD,\,D;@,I%
M?3]?R[BZ4,/BL30IS]I3HXBM2A4T]^%.I*$9Z:>]%*6CMKIH>>U9M;V;7W,\
MS^-/_)'/BQ_V37QU_P"HQJE?Y3_P_P#^1Z\#_P#8W>&?_3U8U_JP?&G_`)(Y
M\6/^R:^.O_48U2O\I_X?_P#(]>!_^QN\,_\`IZL:_J#Z.7_(MXZ_Z]Y9_P"H
M^:GH8':IZQ_)G^M4GW%_W5_D*=34^XO^ZO\`(4ZOY7/."FO]QO\`=;^1IU-?
M[C?[K?R--;KU7YC6Z]5^9_D9ZC_Q^WW_`%]7/_HUZ_UIO!'_`")?A#_L5]`_
M]--I7^2SJ/\`Q^WW_7U<_P#HUZ_UIO!'_(E^$/\`L5]`_P#33:5_4GTD/]VX
M%_Z\9Q_Z;R8[\;\%+Y_E$ZBBBBOY://$/((]J_SM_P#@MQ^QIXW_`&8OVR_B
M)X]DT*];X2_'KQ)J?Q"\">*XK:9](;5]:<ZCXJ\*W5\`\,&NZ5JTMW=&SE:.
M6YTZYM[ZVC>$R^5_HDUX]\=/@'\(_P!I3X=:S\*?C9X(T;Q[X'UQ4:ZTC6("
MQMKR$-]DU32[R)H[S2M6L78R6>I6$\%U`Q90YCDD1_T+PVXZK<!9_P#VE["6
M+P.+H_4\QPT)*-2=!SC4C5HMM1]O1G'F@I^[.,IP;CS*<=\/6]C.[5XM6=M_
M)G\)'_!,W_@MC\6?V$]'T[X0>._"Z_&#]GB&\NKFS\/PW::9XZ\"R:A<-<WD
MW@W6+@OIM]ITL\L]S<>&M:AC@GN&5M/UK1<W)NO[!_V2?^"I/[&?[9CV6C_"
M?XJ6.G>/;Q`P^&?CI8_"?CB27;ODMM-TR_F-MKTD2AV8>'[W5#Y<<DP'DJ9*
M_`/]K_\`X-GO$5BVJ^+OV,/BC9:U:_Z1=1?"+XKRMIVIQHI\Q++PY\0K..:P
MOY9%/DVUGXFTK2(T,:O=>))!*WD?S+?%/X1_&G]E_P")UQX*^)WA7Q7\)_B;
MX2O+;4(8+S[1I&KV4\$HFT_6]#U6RE43P>=$L^G:SI-Y)"SQB6VN=Z9'[]C.
M$?"_Q<>(S/AK-%E7$-:$J^)HTU[*K.L[.53&Y77<>?WG:IB,'*,9MN3JU'J=
MKIT,3[T7:3U;6[VWBS_5VHK^7_\`X))_\%J]%\8?!#Q!X$_;*\?P1_$/X7WV
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MHA)9_9)L/`R#XU^'W_!?+_@IKX#TJWT:?XT^'_'UM9HL-M<_$'X;^#=7U6.)
M58!;C6M*TS0]5U-\OO:ZU>[U"]=E4/<L@*'[S*O`WB+/L@RC/<HS+*JW]I85
M8BI@L36J4*F&4IR44ZE.%>%1N"A)IJFXN;B[M:_CF8^,&2Y/G69Y1F67YA3C
M@,0Z%/%4(1JPK\L8<TO9SE3G&TG**:YHOE34O>T_LB_X+`^'/A)X@_X)T?M2
M'XOP:*VF:+\,M;UWP=>ZLD'VK3OB?IT7F_#B70)Y5^T6^MWOB[^R]*@%G)#)
M>VM_=Z9<R#3KV]5O\[_]EFVUV\_:<_9SM?"_F_\`"2W'QV^$<7A\P+.\RZU)
MX_\`#ZZ6\2VQ6X+I>F%E\AEER/D=6PP]J_:K_P""B'[8O[<,FEZ3\>/BKJOB
MO0-/OH[G0OA]X=T;2_#'A"UU$JT<-S'X<\-6-FNL:DOF2+;7^MOJ^IP+*\-O
M=1Q$1C]W_P#@@[_P27^)5O\`$[PI^VQ^T=X+U#P9X9\&K=ZI\$/!'BJR^Q>(
M/$GB.YM+C3;3Q_JF@7:B^TC1M#CN+J\\*#5[:SO]1U==.\2Z?#_9MKI=_?\`
M[#D66Q\'/#W/X<39KA:^.S/ZS/"Y;0K<\/K%;!_5J6&PL:BA.K.J[5,14C3C
M3C!)M6@Y/\LS?,)^*/&^35,ARRO1PN!>'CB,;5I*,G1IXF->I7Q$H<T::@OW
M=&,IN;;LOB2/[)$X5<XS@9]S_C3Z,9_`YHK^,3^KXJR2WLDON1^('_!PU_RC
M'^)G_90_A!_ZG>EU_+E_P0!_Y2D_`;_L7?C+_P"J@\:5_4;_`,'#7_*,?XF?
M]E#^$'_J=Z77\N7_``0!_P"4I/P&_P"Q=^,O_JH/&E?U1X<?\F*X]_Q<1?\`
MJFP)_-W'O_)X.$?\60_^K.N?Z)E%%(02"!7\KG])'E?QT!D^"?Q@CC#.[_"_
MQ\B(BEF=SX5U4!54`EF)(``R22`,FO\`+P_9%U&QTC]JW]F'5-4NX-/TW3/V
MA/@MJ.HWUW(L%K96-E\2/#5Q=W=S,Y"106T$<DTTCD+'&C.Q`!-?ZJ&M:7;Z
MUHVK:+<EEMM7TR_TNX*?>$&H6LMK*5/9@DK;??%?Y=O[<?[('Q-_8D_:(\;_
M``A\>Z#JFF:=9ZQ=ZE\._$[V]P-&\8^![N[GE\.Z]H.J[?LUZ!:J+348X9FN
M=,UBTO\`3;Z."]M)HE_IGZ/&,P=:'%W#];$4Z&+S3"X:>%C.24JL(4\50KNG
M%VYY4G7I2<4^9QDW:R;7\^^..&Q5*KPSG-*A4K8;`8C$1KRBFXPJ2J86K24V
MHOE5149I2=DFDMVD?ZD<;!D0KR"J\CZ#GZ?2GU_F?>#O^"P/_!2GP'X9T;PA
MX:_:Q\>0Z%X?LH=-TF'5]'\#>)[ZWL;==EO;2ZWXG\*:QKEZEO&!#`;[4;EH
MH$C@1EBC1!TG_#Z[_@J)_P!':^*C]?!'PG_IX!%>9/Z./%JE)0S7)I04GRR<
M\3%RC?1N/L7RMK=7=GI<]"EX[<-^SI\^6YI&?+%2BE0DE*T;I2]HKV;:6BO:
M^ES_`$G:*_D;_P"""?\`P4._;+_:S_;"^(OPX_:'^..M?$OP5HW[-WC'QKIN
M@ZCX=\$:1!:^*--^)OP?T.QU=+GPUX8T6^>6WTKQ'K=FL$UU):,E^\CP--%!
M)%_7)7Y!Q?PKCN#,[K9%F-;#U\51H8>O*IAG.5)QQ--5().<82ND[2O%:GZA
MPMQ)@^*\IIYQ@:5:CAZE:O04,0HJHI4)<DG[K:LWMK?R/Y*O^#I7Q\(_"W[*
M?PNBFPUWK_C_`,>7T'F#+K8Z=H_A_2Y?+#;L1M?ZN@9EVGS2%;*LIT_^#6[X
M>FV^'_[4OQ3FA`.J^+O!'@BPGV\O'I&D:CK.I1ES&.(GU73F"I*X_>Y=$.UF
M^"O^#F'X@GQ%^VYX`\"+,\L7P\^"6B2-'N8QV]YXMU[7-1FC52=JRFUL;*:0
MJ.4ECR200/WC_P"#=GX:GP/_`,$VO"'BB2`Q3_%WXG?%#QZS2#$LEOINO#X;
M6AP79UA*>`&G@5UB#+<-<1QLEPL\W[EG5LD^CUDF%MR5,]QU"<D_=;=?&5\P
MNE+67-0PL-NCYE='X[E/_"OXVYKB/BAE&&K*-M;>RPU'"-/MRUL1*VUFMKO3
MX=_X.?OV>!K/P[^`W[3NE6(-[X+US4/A1XJO8X_F;0O%`FU[PV+F0`DQV6LZ
M?JR6H;:L;ZO='):55K^;'1OVV/&.F?\`!/\`\7?L-,]^V@ZW\>]#^*VG7PE#
M06_A_P#L"YB\1>&26E#P6K>*=)\.:_9VD,303W6H:]<W#QR^2LO^AA_P41_9
MPMOVL/V,?C[\$O(CEUSQ%X%U'5?!4CD)]F\?>$]GBCP5)YQ*F""?Q#I-C8:@
MZ,I?2[V^@?=%+(C?Y>%S;W%I//:W4$MM=VTTEO<6T\;PSV]Q"YBE@GBE"O%+
M%*K1R1R*KHZLKJ""*^R\"\;@>).#XY+F<8UZW"F<TL=@U4:O1A*H\9@ZT>J5
M.O\`6J=[VY'*#]W0^6\8,'B\BXJEFF!E*C1XBRRIA<0X)I5)<D<-B:4MK\]-
M49I+7F7,M6?UO_\`!K]^S?)-??M!_M7:WIY^SVD6D_!3X?W<H4J]W+Y/BSXB
M7,<;J65[>V/@:QM;N(X=+[6;0G*2I7TE_P`'07PSCUS]E[]G_P"*\-MY]_\`
M#OXUWOA.2953=9Z#\2?!^IWFH3M(S*5B?6?`/AFV:*-7:26XA<A4A9A^K7_!
M)_\`9[7]FO\`8(_9\\`W-C]AU_6/!UM\0_%<;QB.X/B+XA?\51>1W2E5D2XM
M+?4+2QDBFS+;FU%LVT0A%\6_X+L_#]O'W_!,WX]K'#YD_@U_!GCR"0('DA7P
MSXKTNXNY$^5BNZQEN8';Y?W4T@W+NR/R-\7O,O&_"9]&K;#+B.AEN&FG>,<`
MI?V4I*[LE6I3J59V:UJR:ULC]-7"ZP'A%B<GE37UB62U,QKQM[TL;*V/L[;R
MA.,*47VA$_'7_@UG^(R1ZY^UK\)+FZ(>XTSX:_$31K/<Q#"VN_$GAOQ)<A"V
MT%#=>%8MRIN8/B1L)&*_K:^(>@+XJ\">,/#;)O\`[;\-ZUIBH>0TEYI]Q!$#
MW_UCKTYK^"3_`(-T/B1_P@__``4?T/PX\XA@^+?P@^)?@!ED*B*2>QAT?XDV
M@)9659C)X`,4#AHW+3-;HY^T-#-_H%$94ANXP?3\?8__`%J\SZ0.41AQUG$*
MD;4L[RS"8BVMG"KA/J%1O97<\-4;2NGO>[9T>#V+CF'`F'PLWS?5,1CL#-=5
M&4_;I6[*&)BEY(_E(^$7B2;X8?&GP'XBN2T3>$O'6EG4QRI^R6VIK9:M$=X^
M0R6;W4+$@%=Y)'!%?U/:E8Z;XH\/7VF72P7VD^(='NK&=&5)[:[T_5;*2WE4
MJP>.:*>WG8%6#)(C$$,I.?YT_P!NGX/3?"KX[^(+VTMFB\,_$":7QCH<J*?*
MBN]0E,NOZ>IP%0VFK-/-!%&-D5C=V:+RK*OZN_L'?M`6GQ=^%%CX6U:ZC'CC
MX=VMIHFK02R+YVIZ3#'Y6CZ]`I(9UE@C%G?[1^ZO[>1RL<5U;!O\YO`',Y<%
M\9<7^&V:S>&Q7]HSQ>5*H^55:N$;A.--NUY5\'[#$0L_>C2?+?<SX!Q/]C9S
MG/#6*E[.JL1*KA>9V4Y4KQDHO2\JE'V=6/=1=C_.O_;(_9U\2?LF?M-_%SX%
MZ_9W-D_@;Q?J$?AVYF$N-4\(WLQU'PCK5I-*`]Q;W^AW%E,DYRS2B5),2I(J
M_P!V?_!'K_@HUX+_`&U_V>O#?A/Q#XELX/VB_A5H6G^'?B/X6OYO*UC7['2[
M:"QTOXB:6L@5=5TS7H(T&JR6C23Z9KD=[#J$%M!<Z9<7W*?\%BO^"5MI^WQ\
M/=.\?_#"'2M(_:5^&FE7EMX6N[QX-/M/B#X=#2WO_"`Z]JDFR*V9;UYKGPQJ
M=^_V32=0O;R*YEM;#4;R>/\`A)MKO]H#]D+XQL]M-X_^!/QK^'.LO%)L-_X8
M\3Z'J%G.4DCD7Y%O=/N6B8,KB\T;6;)LXO;"XS)_K_263>.G!."P<\;1P'%^
M10AS>TM*:K<D:-2JZ>E2K@<>H1G)TM:5:,;W=/EE^X>YBZ25[5(V^3V;\T^O
MR\F?ZM%)D>O6OX@O@I_P<S?M/>#?#MCH?QF^$'PZ^,6IV5NENWC'3KR\^'VM
M:F8X]HN]7TS3+/4O#TM[.^&N)-'T_0[+D^1IT?2I?C+_`,'-/[3/B[0+O1_@
MW\&_AQ\)M3O+5K<>+=6OK_Q_JVFO("&NM*TR^M=)T)+N'K;OJMGK%GO^:>PF
M4;#^/_\`$"?$7ZY]5_LW">RY^7Z]_:&'^J<M_P")\7UGEMK;ZMS]HLY?J=:]
MO=];]#^Q;Q7^T)\$/`OQ(\'?!_QA\4_!/AKXG_$&VOKOP7X(UG7[&PU[Q'#I
MQA6Y_LZTGE0R2GS@;6W=DN+\1736$5RME>&#V($$9'2O\K/3KS]IK]L3X]V%
MW8:A\2/C7\?_`![XAMY;#48;K4M7\4W&K-/YT%Q!=Q.J:%INDX\Z*2)].T;P
M_86^^/[#8VG[K_23_88^&_[1'PF_9E^&W@7]J3XGP?%KXQ:-IKQZ]XG@M8D-
MI9,X&C^'+G5D2*7Q5>Z!8+'8WGBN]@AO]:G5Y[LW,BF^NN3Q%\-</P%@\IE+
MB'"X_,\9%QQF6Q@Z=:E*TF\10BN9O"1:5'FK^SG.IK"Z;C!5\.J,8OVB<GO'
MKTU6FWK^FOPE_P`%Y/V7-=_:1_80\5:MX+TB?6O'/P+UNQ^+6E:;:1M+?:CX
M<TN&>P\>6EE&N3)<6OAB\NO$2Q*IEN!X?-I;J]Q<QQM_%W_P3=_;#N/V'/VL
M_AS\<;BTN]5\'0RW/A3XDZ18%3?7_@'Q)Y5IKDVGQR,D,VJ:.4MM<TZ"62%+
MNZTU+%[BVCNI)X_].2YMX+RWGM+J&*XMKJ&2WN+>>-98)X)D,<T,T;@I)')&
MS(\;@JZL58%217\/G_!7K_@B9X[^"7BCQ?\`M(?LJ^%M2\:_`[6K^]\1^+_A
MWX>LIM0\3?"2ZO9Y+O4+C2](M%EOM:^'\<CRW"7%G!+=^%;0F/4XFTJV;5(_
MMO!GC'):F59IX=\45:='+\X=;ZA7K35.E*>,IQHXC!RJMI4JDY*-7#2DTG5<
MX7YG!2VPE6/*Z,W:[TOUOHUZ]KOT/[4_AS\1?`WQ;\%>'?B)\./$ND>,/!?B
MO3;?5M`\0Z)<QW>GZA97*!T=)$^:.5,F.YM9ECN;2=9+>YBBFC=%[8@?W1^7
M^<?6O\QS]CC_`(*1?M;?L(ZM<1?!;QY(/"%U>-/K_P`)_'%G/XA^'NJ78`26
MX?09KFSO-!U1@J+/JGAK4-#U2X6&&"]N;FVB6WK]F++_`(.B?CS'I"V]_P#L
MO_"R[UORMK:K;>-?%%EIYFP/WHT>33+N94R#^Y.K,?F'[WY>?(S[P`XQP6-G
M')%A<ZRVI4OA\1'%4<+7C2D[Q^L4JTX14H*RE*C.I&=FXQ5^51/!U$[TW&4-
M;:ZK7;S]3^TM3GMC'\^_:EK^*[]E;_@XD_:%\6?M=>!O^&E&^'_AW]G3Q:[>
M"M9\,^$/#2:99^"[W6[ZR31_B!<^(M3GU?Q-?3:-<QK::O%<:O!H']BWVHW@
MTBWN[:WNH?[2[:X@N[>"ZMI8[BWN88YX)X762&:&9!)%+%(I*O'(C*Z.I*LI
M#`D$&OS?B[@C/N"<5A,+GM"E3GC<-]9H5,/5]O0DE+EJ4O:J,4ZU%N/M8JZ2
MG!J4D[F%6C.DTI6U5U;7U1YS\:?^2.?%C_LFOCK_`-1C5*_RF?!%Q!9^,_!]
MU=2I!;6OBCP]<7$\AVQPP0:M9R2RR$_=2.-6=B>B@FO]9GQ%HMGXD\/ZYX=U
M`,UAKVD:EHM\J'#&SU2SFL;H*3G#&"=P#@X..*_S#OV[OV,?BG^Q'^T!XT^%
M/C_P[J-KX?36;Z_^''C%;.X_X1SQOX*NYWN-$U71=4\L6D]Q!921V.M:>DIN
M]'U:WN["[16C1Y/V[Z..88&-7BG):^)IT<9F5#`U<+3G*,9UJ>'CC*5?V2E\
M<J?UFG)QC>5G?8Z\#)+VD6]7RM?*_P!^^Q_I[Z-JVF:]I.F:UHU];:GI.K6%
MIJ.FZC9RK/:7UA>P)<6EW;3(2DL%Q!(DL3J<,C`UIU_ED>"OVW/VQ_AOX>T_
MPE\/_P!JG]H7P5X7TF!+;3/#OA;XP>/=#T73[=,[(++3=.UVWM+:%-S;8X8D
M1<G`&:ZO_AXO^WY_T>I^U-_X??XE_P#S25SU?HU<0*I4]AQ%D\J//+V3JT<;
M"HX7]WVD84IQ4[?$HSDK[,3P,KNTXVZ:,_U#*:QRC$?W6_D:_P`_;_@E?^W!
M^V5\2?\`@H-^RYX%^(7[57[0GCCP7XD^(%Q8^(/"GBSXO>/-?\/:W9+X7\07
M(M-5T?5-=N;"_MQ<00S"&Z@EC$L4;A=R*1_H%,,J1Z@CT[5^2<=\#8[@#-<)
ME>88W"8ZKBL%#'QJX.-94XTY5Z]!0DJT(2YU*A*3LFK-:WNES5:3HSBI-.]I
M75]K_P#`/\C+4?\`C^OA_P!/=R/_`"*]?ZPOP<\5:#XW^$WPS\7>%]2M=8\/
M>)/`7A+6='U*RGAN;:\T_4-"L;BWFBF@DEA?,;@.$D;8X9&.Y2*_S?/^"E_[
M#_CC]AW]I[Q_X$U+1-2'PO\`$&OZMXF^#GBY[6=M)UWP/JU_<7>EZ8-1V?9G
MU[PU#*NB:[9B03I=6@O?)2TO;5G^?_AQ^V!^U=\'O#\7A/X4?M*?'3X;^%[=
MF>W\.^!_BIXU\,:+`SL7<PZ9H^M6=G%N=F=MD*Y9B3R:_JOCO@B'BUD/"V8Y
M#G.#HQP>'JU:-2O&=6A6HXZEA/:0FZ'/4I5Z,\+&+A*FVI<\)\DHGH5J2Q$*
M;A*R6JNM+-+U[=S_`%3**_R\_P#AXO\`M^?]'J?M3?\`A]_B7_\`-)7U!^Q%
M^WI^V[XP_;1_9#\)>*_VNOVD?$OA;Q3^U!\`O#GB7P[KOQH^(6J:)K^@:W\5
MO">F:SHNL:9>^()K/4=*U73KJYL=0L+N&6VO+2>:WGCDBD=3^08_Z.W$67X'
M&X^IGV2SIX+"8G%SA"&.YYPPU&=:48\U!1YI1@U&[2NU=V.=X*:3?/'3R9_H
MV54MK^QO'N8K2\MKF2SG-K>1V\\<SVMRJ)(UO<K&S&"=8Y(W:&4+($=&*A64
MFRYVHQP3A2<#J>.@K_-=^.7[=G[6_P`,_P!M?]HKXN_#'XG?%KX(Z_XL^+GB
MW4G\/23ZKH\4FE66L75AH%IXE\#^(K>31]0,.DVMIYEAKFB744<N\&$$"OSK
M@'P_QO'V(S/#8+'X7`U<NPM+$1>*4G"O4JU'"%%<CYXWC&<G-1FHM13C[R9A
M1HNLY)-1LM+ZWVN?Z4?&>ISD<9Z?AD?CUK^57_@Z'TCX5CX3?LSZ[<?V7%\:
MA\1_$.EZ+Y8B36+SX9/X8O+KQ2;S8!-/IVG>*8/!@L#<LT=M<ZEJ`LMK75[N
M_);3O^#AO_@I78Z`=&N?&WPNU?4#'Y8\5:E\)_#T>OJVP+YRP:3)I?ACS<@R
M$-X<:'>S?N@@1%_,KXJ_&3]IK]M[XN0>(_B3XC\=?'7XL>)9XM*T:PL]+.H7
MA$\X%MHGA3PCX8TZWTS1[$SR#R=)\/Z196GFNTGD>8[N?VKP]\&.)N%N*,#Q
M#GF897@L#E3K5I/"XR=2>(YJ-2E[.4IT:,*5!J;E5E4E=QCR\EWS1ZZ&%E3J
M*<Y+EB^F[_R[6/GVST[4M0\S^SK*\O/)V>=]DAGF\OS-_E^9Y*-MW[)-F[&=
MC;<X."O[M/\`@D7_`,$?]*_9X^!>N^(/VJO!.@:U\8/BU?:'K5_X4ODT[7(_
MA[H&B6VIIHGA^6[5;NR;7)_[:O;[7_L$DD$,[VVG_:;IK#S:*VXG\:\CP^?9
ME0P6"698:A7C1IXZDX.GB'3I4H5)TY->]356-2,)[3C&,EHU=5,3!3DEJD[7
M7HO^#_6_[S>-/A[X$^)&CR^'OB!X.\,^-M#F#B32O%.B:=KMB?,7:S"VU*WN
M(D<KQYB*KX`^;@5\,>)O^"27_!.'Q9=F^U7]D;X20W3RK-))HNCW?AY99%#C
M,L>@WVG1RJV\[UD5D<A"ZL40C]&**_F#!YQFV7)K+\SS#`IO6.$QN(PT7YM4
M:D$WZH^>Q>597CW?&Y=@<7+^;$X6A6EZ*52$I)>2=CY"^%/[`O[%_P`$;^'5
M_A;^S/\`!_PAK%NP>'6;'P9I5QJ\;J_F)(FHZA!>7B2Q/S#(DP>(!1&RA1CZ
M\`"@```#H!2T5ABL;C<?4]MCL7BL95V]KBL15Q%2W;GK3G*WE>QOA<%@\%#V
M>#PN&PE/^3#4*="':[C2C%-^;5PHHHKE.D\V^+'P=^%GQV\&7OPZ^,G@+PQ\
M2O`NHW>GW]]X4\7Z7;ZQHEW>:5=)>Z=<SV-RK1/-97<<=Q;N1F.5%=>17B?P
MK_8-_8S^!_C;2_B1\(/V:/A!\.?'NBPZC;Z3XM\)^#M,TC7-/AU:PN-*U.*U
MO[:-9HDOM.N[FRN54@2V\\L;?*QKZUHKLI9CF%##U,)0QV,HX2MS>VPM+%5Z
M>'J\\5&?M*,)JG/GBE&7-%\T4D[I(XZN7X"MB*>+K8+"5<52Y?98FIAZ,Z]/
MDES0]G6E!U(<DO>CRR7*VVK-L****XSL`C/!KR;XM_`?X,?'K0D\,_&CX7>!
M_B?H,3M)#IGC7P[INO6]N[[=[VWVZ"5[9I-J^8T#QF0*H?<`*]9HK6C6K8:K
M&MAZM6A6@^:%6C4E2JPEWC4@XRB_--,RK4*.(IRI8BE3KTIJTZ5:$:E.2[2A
M-.,EY--'P/\`\.L_^"<_7_AC#]GW/K_PKS1O_C-)_P`.LO\`@G/_`-&8?L^?
M^&\T7_XS7WS17I_ZQ<0?]#W./_#GC?\`Y>>;_J_D/_0ERG_PW83R_P"G/DCY
MC^"_[%W[)_[.GBF_\;_`K]GWX6_"GQ=J>@W7A;4/$7@CPKI^AZK>>';[4-+U
M:[T:XN[2-))-/N-2T32;V6W8['N-.M9"-T2U].445YV)Q6*QE5U\9B:^*K-1
MBZV)K5*]5QBK1BZE64IM16D4W9+1'H8?"X;!TE1PF'H86BFY*EAZ4*--.7Q-
M0IQC%-[MI7;U>I\F_%;]A+]C?XY^-+_XB_&']FSX1?$CQUJEM86>H>*_%WA#
M3=8UN\M=+M8[+3K>>^N8VE>*RM(H[>W0G$<2A5%>_P#P\^'7@7X2^#-`^'7P
MS\)Z'X&\"^%K1['P[X4\-6$.EZ'HUG)<SWDEOI]A;JL-O')=W-Q<NJ*-\TTL
MC99V)[.BM*N/QU>A2PM?&XNMAJ'+[##5<36J4*/+%PC[*C.;IT^6+<8\D5:+
M:6CL12P."H5ZF*HX/"T<36NJV(I8>E3K5>9J4O:5804YWE%2?-)WDDWJ(RJZ
MLC`,K`JRD9!!&"".X(ZU\,:E_P`$R/\`@GSK&JZAKFJ?L>_`2_U?5=1NM6U'
M4+GX?Z-)<WNI7US)>7=[<2-#F2XN+J62>5SRTCLQZU]T4487'X[`^T^I8W%X
M/VJ4:OU7$UL/[6,;\JJ>RG#G2N[*5TKNV[#$X'!8WV?US!X7%>R?-2^LX>E7
M]G)V;</:PER-\JNXV>B(XHHH(HX88TBAA18XHHU"1QQHH5(XT4!41%`554!5
M4```"N9\;^!_"'Q*\)Z]X$\?>'-)\7>#?%&GS:3XB\-:[9Q7^CZSIMQCSK'4
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ME^SS8?M"?#*\T2#R;3QCH1?5_!NJ2*,0ZE$G[W3KE@-QL-6@4V<XS^XE:WO`
MKM;"-_Y\/`?CCXB_LX?%!=8TP76A>*_"FJ2Z9KVAW\;I#?0V]RJ:GH>K6KA6
MDM;M$,1==DT),5W9S0W$<$Z?U8U\.?M7_L8>&?C]9S^)O#K6?AGXH6D"BVUA
MH2+#Q!%`F(].\0K"OFL0@6&TU1%FN;-0B/%=6R+`O\W>,WA3F'$-?"\:\&SE
MA>,,G]G4<*,_8U,RIX=\U%TJETEC:%N6FYOEK4OW,GI!'PW&7"N(S&I2SK)Y
M.CG&#Y7:#Y)8F%.SARRT2KT]5%R=IPM3>T;>L?L^?M+?#_\`:$\.1ZAX<OH;
M#Q'9PQ'Q#X1OIT76-)E<!3(L;",WVG2296WU&V1X'.(I?*N`\2\=^U#^PC^R
MI^V-HYTOX_?"/P]XNO883!IWBRV%QH/C?1P`?+.F>+M$FL=;A2)CO6SFNY]/
MDYCN+.:&22)_P*\4>"_C%^SIXU@&KV7B+P%XET^=GTK7+*2XM;>]$94F?2M5
MM_\`1=0MV&P31QRR`*XBNHE)V5]J_"K_`(*:_$SPS!;Z9\2_#6F>/[")4C&K
MV$Y\/^(PH`!DNG$5YI>I%5'RHMEILKL2TMXY/'F\`_2863UZ.7<<T\SX3XER
M^2HU,UPU/$4:<ZD+1=2M2I6Q.$J27O5%&-2A/5PM%J"X\F\1:5)K!<14JV6X
M^C:%2O[*?LIR5DW4IQ3J49/>2490=KJR:BOD7X@_\&NWP1U769[KX8_M1?$[
MP3HTTTDL6D>,/`_ACXAW-K&[2-]GAU72]6^'A>*+=&D#W-E-.(X\3RW$KF86
MOAM_P:]?`71M6CN_BM^TQ\4_'NE13))_9/@WPCX8^&[7$:8)M[O4=2O_`(B3
MM#*05D:SBL;CRCB&>&0B9?UOTC_@IU\!+Z`/J>D>.=$F"_/!<:3:7A#@@%5?
M3[ZY5AR2&.W@<@$XJQJ/_!37]GVTMFELK+QOJLPW8M;?18;:1CQ@![Z\MH><
M\9D`&#DCC/\`3"^EO2GA$EXMX=473M?VE%5^6R7Q_4EB.:VE[\^NFK/M%QMD
M+ASK/,):W-?G?-LG?E<>:_=6OY7/:?V8_P!B7]F']CO0GT+]GSX2^'O`WVJ!
M+?5=?076L>+M<52K$ZWXKUNXU#7K]&D42_9Y;[[)&X406T4<<:)WGQN_:`^'
M7P%\-2:]XUUB-+R>.5-$\.VTB3:WKEV@R(;*S!WB)"5-S?3".SM591++YDD,
M<GY5_%/_`(*?^-]=@GTSX5^#['P;;R^9'_;_`(AG77=;V,`5DL]/@6VTK3IQ
M\RLUR^MHRDF,02!7'PQHOAOXT?M+>.)FL(/$?Q"\57KJ=0U2[DFN+;3K=W(#
MWM].PLM+LHB6\J'?#&<,EO"[Y2OYMXZ^DOA\QQ%;`\$T\QXPXGS"?LJ>8XBE
MB:U"%66D:L8U4\3C9Q?P0M"DK7E/E7*_C\W\1</)O"</TJV:YA5]RG5]E4=&
M,GHI1A;VE9KI'EC%6UDUH_TV^!/_``4DC\0_$#7-(^,5KI_AKPKX@U19/"&J
MV<3&W\+P%(+:'2=<N$7S+JUF\L7LNLRQJ;>]N+P2K#IGV:&P_6FTO+/4[6&[
MLKFWOK*ZACGM[JVEBN+>Y@F0/'+#+$6BDC=&5D=&965@02#S_.Q\7_V!_C5\
M*O#VG>);6W@\>V)T^.Y\00^%;6ZGOO#]YR9X/L1#76IV$*[3_:-K$I/[QIK.
MWBB\U_-?@W^U?\:O@88K#PMXA_M#0()BTGA+Q/'/J>BKM8"6&"'S[>]TW)'S
M#3KNT`?+%26??\9POXU\7\!8MY%XMY1FCA7F\1ALW]@OK5*->2J.$HPM1Q="
MFYVBZ$_:T$O9.,THJ/DY7QIFV0U?J'%V#Q2YY.I2QC@G5A&HU)QDH^Y5IQOI
MR24Z=N1IZ*/ZG?M,?\$B?V"_VJ;N_P!=^('P5T_PYXTU$N\_CWX97EQX"\4/
M<R##7=W_`&0/[!UFY]'\0Z%J\8.6,98DU^8.J_\`!K]^RO+J(DT7]H;]H.PT
MG<A-GJ<7PXU?42@<EU_M.T\'Z);!FB(17_LC"R`R%'4^6/T-\%_\%3_!EU;P
M1>/_`(<>(=%OL*DUUX<O['6M,=N`\PBO?[*O;96.66`+?,JG:9W(W'UE?^"E
M?[.;!6,GC!3@$I_PC\IVDC)4E9B"5Z9!(XR"17]5</?2FRC"8*G'*/%*6#PW
M+%1PN*Q-:,J"LDJ:HXVC-TN5:<M.T5KRZGZ#A^-^'ZM-2IYUAXII/EJRG3G&
M^MG&I%23Z/=;JY\L?`#_`(($_P#!/'X'7ECK>J^!_%OQS\1V$J3P:E\9O$R:
MSIL,X(8F/PEX:TWPIX1N80Z@PQZSHNKS0``K<L^Z1_V?M;6PT?3K6PLH;73=
M-TRT@M+2U@6*VM+&QM(5AM[:"-`D4%O;P1I%#&@6..)%50%`K\Q/%G_!4;X;
MV5O*G@GP'XJ\1WPSY+ZM<V'A_3">0#),G]JWQVX#&-=/`=3@2HW(^#_BK^V%
M\9_C2+G3]6UF+PWX:N"RGPSX66XT^QF@8X2+4;M[B:_U)BF%F\V>.VE;>4M(
M8V\E?@N.?I0<-5Y.M6XBS#C;-(J7U>AAZE>K0A)V33Q%>,</AX-VYW1A-NVD
M)25CRLS\0LBPT;4<5+,\19J%+#*3A=?SU914(J[U<5.6^FQ_1LDB2('C99%(
M!5D8,&!Z$,N0?7(KS;XI_!GX3?&[P^WA3XO_``Z\&_$CPXS^:-'\9:!INO64
M<N,&6"/4+>8P2%?E:2!HW9?E8D<5^(_P3_:H^+?PL@M-+T[64U_P[;^7&GA_
MQ()]0M((`H7RK&Y6>&_L%13^X2&Y-M$0BFVDB7RZ_1?PC^W/X1UJ"%/$?A'7
M-&O&4>8VGW-IJUB#CDK(XT^ZP2.$-HV!UD)Y,\)>./">=1HU9XS$\/9G#E<J
M6)]K#V56V]#&4$DUK[LG[*5M7&+T-LJXUR?'PBZE6>!Q%ES4JRE92Z\E6"<9
M+M?E?=+4K_\`#K?_`()V?]&:_L__`/AO-$_^,4?\.M_^"=?_`$9K^S__`.&\
MT3_XQ7MEC^TY\-M1*_9VUKYAC#Z:ZCUZ[\=".GK710?&;2=2(72=+O96;`$E
MV\5O&`<'.U3-(V,_=*QYQ]\5^K4O$AUTG0XPQ]>]K*EFN.FW>VR57S6Y]%#-
M\)4_AXZ,^RA.4F]MK>J/(OA__P`$^/V(_A5XRT#XA?#?]EWX,^"O''A:\;4/
M#GBGP[X)TG3M:T6^:WFM6NM/OH(5EMIS;7$\)D0@^7*Z]&-?8@&,\GGU[?2N
M6\/:K=ZIF:YVC*Y"1J5C7(/W02S$]/O,?;L!U5==3,L5FO)B<5B\5C)*/)"I
MBZ]7$35--R48RK2G*,>:3?*FDFV[7;.M5/:I3YI23V<FV[;]3SGXF_"#X6_&
MCPY+X0^+/P^\(_$7PQ,69]$\8:#IVO6`=EV-)%#J%O.()F3*&:`QRE"5+E3B
MOD__`(=;_P#!.S_HS7]G_P#\-YHG_P`8K[VHKKPV;9K@J;HX/,\PPE)R<G2P
MV,Q-"FY/>3A2J0CS.RN[7=BU.:5E*2792:7X,^"?^'6__!.S_HS7]G__`,-Y
MHG_QBM[PK_P3?_8.\#^*/#?C7PA^R=\#_#GBWP?KVC^*/"_B'2?`FCVFJZ#X
MB\/ZA;ZMHFLZ9=QP"2UU#2]2M+:^LKB,AX+F"*5"&4&OMBBMI9_GLXRA/.LV
MG"<7&<)9CC)1E&2M*,HNLU*,DVFFFFG9Z#]I4_GG_P"!2_S"O`OB_P#LK_LX
M?'Z-H_C/\$OAI\269=ANO%?A'1]3U`)M"*%U.6U&HKY8`\K%U^Z(!CVD9KWV
MBN##XG$82K&OA<17PU:'PUL/5J4:L?\`#4IRC-?)HE-K5-I]T[?D?EK/_P`$
M6?\`@F5<ZE_:;_LJ^$$F`<""#7_'-MIQ\PLQSI5OXICTXE2Y"$VQV`(J86.,
M+]@?!K]DG]F7]G@!O@I\#?AK\-[C88SJ'A?PII=EJSJP8.'U;R'U-_,#,)=U
MV?,!(DW#BOHJBO1Q?$.?X^DZ&.SO-L90=KT<3F.+KTG;:].K6E!VOI=%.I-J
MSG)KU?X]_F(5!ZBBEHKQR`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`I#T/T-%%`'+^*/!GA3QUH\^@^,?#VD>)='
MN3^]T_6;"VO[8OM(65$N(W\J>/<3%<1%)H6^>*1&`(_./XU?L&?`"VM;G5]!
ML?$_A>=O.F^S:)KJ&R4HA8(EOK&GZMY<9(Y".&QT8445^->+^391B\DJ8K%Y
M5EN*Q4/=AB<1@<+7KPCR_#&M4I2J17DI)'R?%N#P=;+YU:V$PU6K&RC5JT*5
M2I%76D9RBY)>29^-/C[PU8^%M>DTO3YKR:W2(.'O'@DF),DB\M!;VZ8PHZ1C
MG/-+\/\`PQ8>+->32M1FO(;>0)N>R>"*?F2-.&FM[A.C'&8SSCW!**_AV.7X
M#ZXH_4<)R^U:Y?JU'EM?:W):WD?A?U?#^V2]A1M[2*M[*%K76EN4_9'X)?L'
M?`&ZMK36=>L?$WBF?RX+DVNN:Y$+!F=0S1O;Z/I^D^9%EONN[-@#YNI/Z/\`
MA+P5X2\!Z1#H?@WPYH_AK2+<_NK#1K"VL;?<6PTLBP1H9IY/O2W$QDGF<EY)
M&<EB45_<?@]DV3X3(:>+PN59;AL5.*C/$X?`X6CB)QM%\LJU.E&I*-];.35S
M]RX2P>#HX"G5HX3#4JLHVE5IT*4*C7+#1SC%2:\FSIG&6`/(.,@\@\]QTKYG
M^+'[)OP&^*DESJOB;P+86^N3^9+/KWA\G0M6N)2"QFNY[!8XKV<G&9[V"XFP
M%3S-@"T45]]Q9EN79EDN-I9C@,%CZ<*%2<*>-PM#%0C-))3C"O3J1C)+:22:
M[GOYGAL/B<)5AB</1Q$5&ZC7I4ZL4[K5*I&23\[7/QW_`&B_V9O`'PJ>27PQ
MJ/BJ17BNYU@U34-+NH8C"<(D9@T6TG*`=?,FD<_WZ^#\G!]@N.F.<9HHK_.[
MB'+,MHYEB(4<OP5*"K22A3PE"$4N9:*,::2^X_G?,<-AX8NK&.'HQ2>BC2II
M=>BBD?>_[.'[,_@#XJ)%<>)M0\51@"TD:#2]0TRUAD\U4+JYFT6ZG"_,0/+F
M1@,?-Z_L5\*_V6O@=\*Q:ZAX8\$6$NL0!6AUS7"=;U:%V4DR6US?"1+27!*B
M6TB@DV,R%RI(HHK^B/`K(LDJ59XBID^53Q%.*G3KSR_"2K4YJ,;2A5E1<XR7
M249)^9^A\#8'!2<JDL'A74BHN-1X>DYQ=J>L9N',GYID7Q$_9;^"7C-KK5K[
MP=:Z3JTI:XFU'PVW]ASSSL2SRW$5H@LYY9'R\LLMJTLKDM*[DFO@CXA_!WPO
M\/KN9-$O-<G2.)Y474KJQG"_)(X0&WTVU8H"H`W,6QU8GFBBOHO$C*,IP^90
MJT,KRZC4J6G4J4L%AJ<YR:NY3G"E&4I-[N3;?5GH\2X3"4\0IT\+AX3EK*4*
M-.,I-MW;DHIMOJV[LI>$QAH_JWZ8%?>7PR\(:7?6]O<SRWI;;&=B2Q+'D\?\
M^YDZ?]-***[>"Z%#GH_N:6R_Y=P_N^161PASKW(_&OLK_(^F+'3;/3K<1VL6
MP``98EW."!RQYR<<UI445^^4DHTX**226B222^2/T"*M%):*R_(****T&%%%
0%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>e38032-13100181121140395e_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e38032-13100181121140395e_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!4`:4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BB@\>I^
ME(#F@!:**3.#C!^O:@!:*/7KQ_GBB@`HHHH`****`"B@'/(HH`**0G&.#SZ=
MOK2T`%%%%`!1110`44F1G&>:,\XP?KVH`6BBB@`HHHH`3G/;'ZTCLJ*S.P50
M"69C@``9))[8%1W$\-M#-//*D,,,3RRS2,$CCCC4L[N[8551068D@``D\"OP
MR_;*_;CU7QO>:Q\+OA)J=UI7@FVDET[Q!XILI7M=0\5/&Q2\M-.N(F2XM/#[
MLK6\K(T<^K1"19<:?.T,_P`'X@>(61>'F3RS/-JGM*]7FIY?EM*4?K6/KI7Y
M*:=^2E"Z=:O).-*+O:4G&$O#S_/\#P]@GB\7)RG*\</AX->UQ%1*_+&_PQ6C
MG-Z13ZMI/[?^/'[?OPE^$DEYH'AG=\1O&=L[0R:;H]RD.AZ=,"5(U37C'/#Y
MD;9S::=!?W&]?+N/LBNLU?F3XZ_X*'_M&>+9IUT76M+\"6,A816OA[38);B.
M,X&UK_55OY7..CHD9#$LA7`QYW^SU^R9\3OVA;[[3H]K_P`(_P"#+>;;J7C7
M6(918-(,-):Z3!\LNLW^&#.D#+;6X(-W=0%XDE_9'X5_L"_`'X<16USJOAP?
M$/7HU7S-4\9!-2L0^!O^S^'6SHJ)N7>C75I>7$9X6X`.*_FW!XGQT\8I2QV`
MQO\`J7PQ6D_J]2G4JX&-2BFK>RJ4HO,,7-Q?\52I4)--*4=G^<4*O'/%[=>A
M6_L3*YO]W*,IT.>&UX2@GB:ST^).%-O1-(_#F;X^?M%>(KII8_BU\6;R?HT>
MD>+?$MJ@+`D?Z+I%Y;P`G:2,1#`4]@:DA^//[1GARY$\OQ7^+5I-E<#6/%?B
M:YB+<L`+;5[N>`E@"2IB.]1R&`K^G_3O#'AC2(([/2_#^BZ=;0#9#!9:586L
M$2J,!8XX((T0`<`*HXXZ5)=^'?#^HQ26]]HND7MO*I26&ZTZSN$D0@@JZ2PL
MK`],$$%?H*]U?1SXHY/:OQ3S98WXU-4,;R*IH_B_M55'KHIZ.VO+T.__`(A[
MFG+=\5X[VV_-R5W&ZMU^N7]'O;H^G\^/@7_@H=^T9X2FA76=;TOQW81$"2V\
M1:;!'<R(I7"B^TI;"56V`KO99&).]RS#YOTS^`_[?_PH^+<MKH'BD-\-O&$[
M1Q1V6LW<4V@ZG,YV)'I6N[8(_.D;'^B:C;V4H+!('O`CR#L/BA^PO^SY\3(K
MB:+PA;>"-<</Y6L^"4CT,>:V6+W6CVR+HEX7D.^:273Q=2DG_2D8[J_'G]H_
M]C+XC_L_R-KB,WC#P"TG[KQ1I=K*LNE,3^[A\062^:=/?D"*]226RG8?ZV"5
MA;CR,9+QV\(?^%'$X_\`UXX8P[3Q/M*E7&SI4$]9575C_:&%=MZD9UZ$':\F
MCDK/CKA%?6*E=9[E=/6KSRG6G"FK)N3FOK%)I:\T95*<;:MK?^@/XD?%WX>?
M"70&\2>//$^FZ'IAC9[42RF6\U%@H80Z;90"2ZOIFR-J6T4GWE+;00:_)[XL
M?\%0?$5]<76G_!_PC:Z/IZ,R6_B+Q9_IFIW*@L!-'HMI*MG8JV%VQSWM])M^
M9O*<F)?S*%WX^^)6J^'_``^;SQ1XWU>*"WT+PWI<]YJ.N75O:(Q%MINEP3R7
M#6UK$SL5@MQ'!$,L0J@D?JE\"_\`@F6)[6Q\0?'/6IHY)XH[@^"/#EP(WMPX
MW_9=6UQ0Q,Z@A+B+2UV(P=(K^7B08R\4/%?Q;Q<LN\.LL?#V54E".,S*4X.=
M*4E'G=;,:E/V=*SYN2CA:4L0X)/63L9OB?BKBVL\-PYAO[.PL%%5L7)IRBVE
MS*>(E'EAK?EA2@ZKCKNSX1\3?M@?M)^+))&OOBQXHL(Y"0EKX=N(_#\,2M_#
M$VCPVMUU)*L\\D@XP_%<J/BU^T@T)N/^%F_&\P8R9_\`A-/';0@`A=WFC4PF
M`?ESG`)P3UK^DCP+\!/@U\-K6"V\&?#CPIHQAC""]72+6[U>8`$9N]9ODN=6
MO7P3\]W>S,`2H(7BO3/[+TK;M&G6&SGY/L=OM/MM\O'7V]Z]JC]'KC3'1^L9
MYXHYF\=-?O(T%C\53A-I.T:]?'T)3BM5_!IZ)6MLNZGP#G=9*IC>*L9[>6LE
M!XFK!2TVG/$TW)?]N1TMIV_F<\*_M??M)>%)8_LGQ7\47J0N%DM/$4Z>($DV
MX!BG?6(KJ[!RI#%;B.3(;+9+9^X?A/\`\%+O$<$MM8?%CPC;:S9-M6;7?"96
MRU.($@>:VDWLWV&\]TAO=/*@[@TA&T_J'XR^"WPF^(%M):>,OA]X3UQ9(VC\
M^ZT6Q6^A5NIL]3AABU"RD]);2ZAE7G#BOS[^+_\`P3>T66*[UCX*ZO-I-V@D
MFB\)>(+N6[TV<@EUMK#69F>]M'(^2$ZBUXA8*LUPBNTL>=3P\\;>`D\;PQQG
M7XGP=#6678BI5E5E!=(8#'U,31E&WV:&*C5DW:,'N1/A_C7(G[;*\YJ9I1AK
M+#U93E.25OAH8B=6#VU4*L92>BCWYKQK_P`%#?%NNW4UK\.?#5GX;TSS-L&I
M:\RZGK$\6?EE>TA>/3[%F7K");_8P)^T/G`\XB_:`^,WB>96U'X@>(1YN[;#
MIER-*1=X("(-+2U<XSA-SNX/W6)&:^B_@O\`\$^=+TNVL]5^+NKOJFH,D<S^
M&=!N9+?3;9B%/V:\U95CO;QD'RR_8A91A\K%/-&HEE^_/"_PS\`>#+:.T\,>
M$/#^CQQJ$+VFF6HN90!@-<WLD;WEU+@#,US/-*V,%R`,?0Y-P9XM<4\N8\5\
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M^15\/:Q<:G`IN4C\S:"6CRN>,\J21D^Q'TKI:R-.T>#3&/V9G\HC`C<EBO7A
M6/)&,#G)XZUKU^AX=58THJL^:HDDY=]%KT>]]]>Y]!34U%*;O);OOIY!1116
MQ84444`%%%%`!129`ZG%`8'H1S[T`+13=P'4X-%`'A?[2'[1_P`)_P!E'X1>
M*OC;\:?$D/AGP/X4MXVGG""YU+5M1NG\G3-!T'3E99M4US5K@BWT^P@^:1R\
MLC16\,\T7\>?[2W_``<P_M+>+]9U/3/V8_A]X%^$?@])Y8M-\2>,M,;QUX_N
MK=)"(+IH+B\@\'Z2TR\S64VB:^5R@CO4(<-L?\'./QW\3:]^T'\'?V>H-3O(
M/!/@'P$/']]HL<TB66H^,?%M]?6,.K7<"[([B?3-!L$L=->42M9K?ZKY+H+^
M=6X/_@@A_P`$SO@5^V)/\4?CC^T+IQ\<^$_A=K^D^$O#7PR.H2VFCZGXBO[%
M-:N==\6)830W^H:?969@MM-T5Y[;3[R:>[FU**_@BA@7^F>"^#.#.&N`X>(?
M&N"EG#Q*C6P>`<?:T84ZM?ZOA:4<.YPHUJV(FN><\0W2IPDO=7*V_P"?.+.+
M.*<_XR?!/"N+661H3E2Q&+C/V=6I.G25;$5'6474ITJ47RQC22G.47[S32/D
M;3/^"^'_``51T_4([R[_`&D=/UJV1V9M)U3X+_`N'3Y@S`A'ET;X;Z1J@1>5
M!BU.-^?F<GD?T(_\$=/^"QG[1W[>'QDU;X&_&'X6>`/^)!X$U/QC?_$[P(NM
M:!':KIMWING6=EJWAK4]0U^VEO=:N+\LMSI^I:?;*UO<-%IL42K&OZI:S_P2
MS_X)YZ]I+:+J/[(WP5%FT7DJ;+PE9Z;=PJ(C"KVU_8?9KVWF2-B$GAG25"=R
MN&P:H_L??\$S/V8OV&/B'\4OB!^S[I/B;0G^*NGZ'I=]X=UO7W\1:1X9L=&N
M;R[:T\+W>HVS^((;/4;FZCGO(-8UK63'+;0K9RVUOF`?.<2\<>%V>\/YGAL!
MP)3R3._9*.5XC#X;"4*2J2J4XRJ5*N!E0ES4X.4XTZM&K2FXVDTW8]SA_@_Q
M#R?.LOKXSBZIF>5*KS9A1JXG$UIRIJ$FZ<*>+C524Y)1<Z=2$XWNE9:?47[2
M'Q5N_@5^SU\=_C=8Z/;^(KSX._!KXG?%*T\/7=W)I]KKMU\/_!6M^*[?1[G4
M(8+J:Q@U.724LIKN*VN)+:.9ID@E9!&W\F__`!%._$[_`*,\\!_^'=\0?_,/
M7]<_QE^%V@_'#X0_%/X+^*KW5].\+_%WX<^-_ACXDO\`P_/96NO66@^/?#6I
M^%M7O-$NM2L-5T^VU>VT_5;B;39[_2]2LXKQ(9+JPO(%>WD_`K_B&$_81_Z+
M!^UO_P"%Q\&__G#?E^N:^:\/L=X9X3"YC'CW*L9F&)GB*$LNGA7B[4Z"A)5X
MS^K8S"QNZG*US*;M>S2N>_QQ@_$#$XK`/@W'T<'AHX>JL;&K]6]^NZB]DX^W
MP]9V5.Z?*XKNGNO@W_B*=^)W_1GG@/\`\.[X@_\`F'H_XBG?B=_T9YX#_P##
MN^(/_F'KG/\`@J=_P1`_96_8=_8]\7_M!_"OXB?M!>(O&7A_Q5X$T.RTOX@^
M*/ASJGAF6U\4>)+/1K^2ZL_#GPJ\*ZJ\\-M</)9M%K,,<<X5IXKB,&,_C3_P
M3"_92^'W[:_[9GPT_9U^*.M^,O#W@OQGI7CZ_P!2U7P!?Z)I?BBWE\*^!/$'
MBC3TL;SQ%X>\4Z5''-?Z3;PWHN-%N6DM'FCA:WF9)X_WK)^&?!3.^&<TXLP7
M#6*_LK*/K?UMU<3FT,1_L6&HXJLJ=+^TY*;]E5AR^_'FDY+0_&,SX@\6,IS_
M``'#>+SV"S+,?JOU=4Z67SI?[76E0I>TJ?4UR>_!\VCLK/J?MS_Q%._$_P#Z
M,\\!_P#AW/$'_P`P]?KO_P`$EO\`@K5XJ_X*4>*_C1X;\1_!7P_\*8_A5X>\
M'ZW:W6B^,M1\4OK+^*-2URPEM[B*^T'1ELUM%TA9$DC><S&=E94"`M\]?\0P
MO["&?^2P_M;Y]/\`A.?@W_\`.&S_`#X_.OT(_8!_X)4?L_?\$YM>^)/B+X+>
M-/C'XKO?BCI'AW1=?C^*.O>"=9M;.U\,WNIWUC)I">$_A]X*E@GFFU:Y6[:]
MGOXWC2!88H'61Y?R/BW,_!?$</YA1X5R/,<)GTXX?ZAB*\L?[*FUB<.Z_.J^
M8UZ;YL,JT5S4I>]+3EEJOTSAG+_%BCG>!J\19KA\1D\95/KM&G]2YYQ="HJ5
MO986G4TK.FWRS3T=[J]_TUX`_P`/SK\$O^"BO_!>+X+_`+%OQ`U+X*_#;P:W
MQX^+OAY8D\96UKKHT'P3X+U&9%F7P_JWB&*SU*>_\0P6[QRZE8:39W$6DO/'
M8WUW'JD5]I]E^WOQ$UUO"_P_\<^)4=XW\/>$/$FN)(B[WC?2=&O+]'5,C>R-
M`&"Y&XC&>:_RD;"V\9_'KXOV%CY[ZS\0?C)\1K*PBFNI6+ZEXM\?>(X;2`S3
M2%F`N=5U5`6);8C=]HS'@SP#DW&&,SC,.(>>IE.1T:$ZF&C4J4(XBMB/;33J
MUJ3C45&A3P\YSC3G"3<H>\E=/;Q6XSS7AC#99@LDY:>8YM5JJ.(E3C5E2IT7
M1C:E3FG"52I.M&,7.,HQ49^ZVTU_3?\`\13OQ._Z,\\!_P#AW?$'_P`P]'_$
M4[\3O^C//`?_`(=WQ!_\P]?4/@G_`(-=_P!GB/POHP^(G[17QIU#QD;*W;7K
MCP;:^!M%\-?;WB1KF+2;#6O"_B+4UM89B\<,UWJ3RSQA97A@9C&.I_XA>_V1
M/^B^_M(9ZX%Y\,?US\/.G]:^SGF'T<(3E!93BYJ,G'GA_K"X2LTN:+>+3<7:
MZ;2NF^[M\G#`>.TX0G_:5&//&,N64\H4H\R3Y9)89I25[.S:33UT/9_^"5?_
M``6C\8_\%%_VAO&'P1\0_`7PU\+K+PQ\&_$/Q2B\0:-XZU3Q/=7=SH?C7X>^
M$TT>2POO#FD10P7$7C::]:[6Y>2.33XH1`RSO)'^_P#7X_\`_!/_`/X(U_`G
M_@GE\9?$GQJ^&/Q.^+7C3Q!XF^&FL_"^[TKQY<>#Y='@T?6_%'@WQ5<:A;+X
M?\*Z'>#4HKSP786\+2W<EK]ENKP/;O*89(OV`K\/XXK<*5^(*]3@RA4PV1/#
MX54:57ZUSJNJ26);^N5*E?WJMVKRM_*DM#]@X.I<24<DI0XKK1KYPL1B'4J0
M=!IT'.]!7PT(4KJ&CM&_=L8.-QQCOWYZ_P">*_C_`/VM?^#D+XU?"[]HWXG?
M#+X,?!3X7WWP_P#AIX[U_P`$+JWCB[\3:CX@\6/X6U:?2-2U>!]#UC2-/T2U
MU&YL[EM-MVM]6E@M6MYKF224R6Z?UL>.O$47A#P7XN\63NJ0>&?#.NZ_,SX"
MB/2-,NK]RQ*M@8@Y^5O]UNA_R:O&_B"3Q9XT\7>*9I9)Y?$GB?7]=DFE8M)*
M^K:K=WYD=F"EG<S[F)522>0.E?IW@3P5D?%>,S^OGV`AF&&P&&PE/#TJDZT(
M1KXFI5E*I^YG3;E&G1M&\G;G;23LU^>^,?%F;\.8?)J&38V>"KXRMB*M>I3C
M3E-T:$:<81]^$[1E.;<K+7EM>VC_`-/?]@G]KSPY^W)^R_\`#S]HC0=+A\/7
M?B8:QI7BOPG'?IJ,WA/Q=X;U2ZTC6='GG"1.Z3&WM]8TQIX89Y]$U72[N2)/
MM(%?9&3SQVX_+O\`C7\?O_!KW^T"8+O]HC]E_4[K]Q?/I/QG\)6TDB@1WRV]
MKX1\8K!&3O=KNTM/"DTFT;(A8,V-TY-?V`KG&#VX_*OS;Q"X;CPIQ?G.2T8R
MCA*.(5;`J3<O]BQ4(U\/%2E[T_91FZ#E)MN5)MMNY]]P-GT^).%\KS2M-3Q5
M2BZ.,:27^UX=NG6;BM(NHTJO*DDE45DE8^6/VT_VI/#W[&O[-'Q._:'\1Z6V
MNQ>!-(BDTGPZMVM@_B+Q%J=W;Z9H>C+>.DHMDN[^ZB-Q.(I9(K2*XDCBED1(
MW_F(_9Y_X.5OCAXZ^/WP\\&?%7X(?"G3OAEXZ\<:#X1N[KPK>>*[;Q-X8M_$
MNLV>D6VKOJ.IZKJ6G:M'I)NUN+VW_L;3S=PQR-#);N%C?V[_`(.?/VCX]#^&
MWP'_`&6M%U%/[4\=ZYJ?Q7\<644I$]OX6\)C^P_"$-W#G#6FO>([_7+NW8@D
M7'@V0`JI(?\`C3L;Z[TR^LM2L)GM[[3[NVOK*X3A[>[M)DN+:="00'BFC212
M00&49K]W\)_"S(,\X'Q.<9[EJQ>.S6>-66U)U:U.6'P]"+P]&=*,)P2G/%0J
MS4IQES)0WB?C/B1XB9UE7%]#+<HS"6&PF6K"?7:<(4I1KUJKC5K1J.<)-PC1
ME"*2:2;G?5:?Z[BN'`*YVD9!['/3%&"&_P!D\_I_C7FGP8\?V/Q6^#WPI^*&
MDM#)IOQ(^''@CQ[I[02"6!K#Q?X:TWQ!:-#('<21&#4(S'()'#H0P=L[CZ+>
M745E:W-Y.XC@M8);B:1CA8XH8VED=CV544L3Z"OY7Q,'A:E>G6]QX:=6%6_V
M71E*,[^G*S^C:%:-;#TL0G:%6C"LGTY9P4T_N?\`P#\OO^"CO[15]X+\/67P
M9\)Z@UGKGC&S-]XIO+60I=67A;S7C33XW0AX7UR:&6&=U(+Z=!=6^-MTQ7X`
M_8V_9@N/VA?&LEYK@N+;X<>$[BUG\27$1:.36+AF\^#P]:SC:8VO(T)U":)A
M-:V;9C*3S0.OBGQL\>:I\7_C'XT\7RO)<S>(_$\]MHT#,7^SZ5#<#3-`TZ(@
M!2+>PAM(2RA?,D\R=EWR,3_1_P#LY?"?3O@O\(/"'@NTM4AOX--AU'Q%<*FR
M:_\`$>H(D^K75QGYV<3L+>,.6\BUMX+=#Y<2BOXDX<R^7CCXMYOG>;N5?A/A
M:HJ>%P<VW1K4Z5><,%AN57CRXJI3JXO$VLZD%R7Y79?CN7X=\;\68S&XN\\H
MRJ7)1H2UISC";C1I6V2JRA*M5>\DN7;;T<#P9\,O!\KO-H/@KP3X1TB:YN;N
MZGLM$\/Z!HNF0--<WE[=W+V]CI]A:6\<DUU=W,L<,,:R33R@!FK^7+]N/_@Y
M&T3PCK6N_#[]B?P=HWCFZTZ>XTZ7XS^/(;]_",T\,CP3W/A#PI:W&F:AK=LC
MHS6.KZM?66GW>8KN'3[ZR*BX^9?^#@?_`(*5ZUX^^(>J?L1?![7+C3_A[\/[
MB.+XVZOIMTT?_":>-L)./!1:!@6\/>$D,7]JQ2,1J7B*6:WFA2#1HWO?S:_X
M)E_\$HOB[_P4.\27FMB\O/AM\`_"VJ1Z?XM^*=SI;WAU+48Q!<7GA/P-;7#P
M6VL>(X[*:&6^G:1]-\/QWEG<:B)I+BVL;K_6GP_\+N&,BX9I<:>(+I8?+%1I
M5,MRB?-2H4\-HL/*M1I)5*]6O&WU?!4E94^5SC-RY8?NV'PM*C2C.HHQA&,5
M""248Q5N5**MT2LEHEIL>8_$#_@K/_P4<^(^KS:QKG[7OQ@T>665I$LO`6O1
M?#32+=29"D$.E>`+7PW9>5$LA1?.BFED"1O/)-*@DJW\-_\`@KG_`,%'_A?J
MT6K:%^UM\5=?*S)+-I_Q&U2U^)^DW2*1NMY;'Q_9^(4AAE4;':Q:SN%!WPSP
MS`2#^W#X)_\`!&3_`()V?!+P[9:+9?L^^'/B)J=O;I#?>+_BNS>.?$VK3A`D
MUY<R7RPZ/I\EQC=):Z#H^CZ<A.(;*,<5/\9O^"-7_!.SXT>';S1-0_9W\+>`
M[^>W:*S\6?"WS/`WB;2IMI6&[MKG3,Z;>/;D[TM=:TO5=.D(VW%E,A*UZS\6
M_"CVRP7_`!#^D\LO[+ZP\KRCF]GI'G^JVYN7=V]MSJ.JCS>X]/K6'O;V?NZ:
M\L>C73M_EL?E;^PE_P`''?A#XCZ[HGPX_;0\)Z)\+=:U:>VTZQ^+?@I-1;X?
M2:A</'!$WBO0]1N]3U7PI:S2-F;5K?4-6TVU8B2[2PLA+/;_`-/C#0_%VB#!
MTWQ!X<U[3@ZNC6VHZ7JNF7\.Y)(Y$,MM=V=W;R*R.C/%-$X96*MFOX5OCI_P
M;M_M8^#OVA_#GPW^"UY9?$SX.^-+J\N=/^,&L"WT&W\!Z3:21-<6WQ%T^.>=
MTU6WBG2/3WT-+F/Q*Z//96FG[;NTL/[#/V'?V5H/V,?V;O`/P`A^(OB_XH'P
MA;W4EQXG\87*22"\U*5;J]TOPWIZ`C0/!^GW1EC\.Z`UQ?RZ;:.4GU"\G>29
MOSCQ3RCPVCA\NS/@O,:53^UH2>*R*$:E>A3P\HS4JTO;7E@I*:]E/!5^9RNY
M4XPA%\W/BJ>'<;P<6IK6G\47%K5.+NEYIZ;Z'0?!G]E/X4?`[Q%XI\3>$-*D
MDU7Q%J,UQ9W.H[+E_#>E3JC-H.B2,H:&P2?S9/,<M=RPO#;3SRI;(S)^U-^U
MY\!/V-?AM=_%'X^>.;+PIH2/]DTC3(HWU'Q3XKU9E)AT;PKX=M2VH:O?R$`R
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M6/V__:;_`.#F/XZ>*;W4=$_97^%_A/X7^']T\%GXT^(5N?&OC>6+(6&]L]#2
MXM?"6CSC:7,.I6WBF%ED"-&K)N/Y@ZM_P6?_`."G6LZHNK7?[6OC.WND='2#
M2O#/PVT33`8Y6E4'1M'\%V.E2IN8JZ364BRQ@12AXP%K]O\`_@GM_P`&Z'A6
M\\,Z%\5/VZ[[7+[5M9L[74M-^`7AO4+OPW:Z);W$2SQQ_$/Q-8RPZ]=:N5D7
MSO#OA^;0UTB>!H[_`%?4VFFL+3]O;;_@D9_P3=L](.CQ_LB_"62W,?E?:KG1
M[B[U;&T#<-8N+N35!)QGS!=A]Q+;LL2?V3$\:>"G"-:6593PC3S_`.KS5*OF
M,L)A,7"<HM1J.&,S&<JV(::;_=1AAY2UIRY7<]'VN%I/EC!2MNTKZWVN^UNA
M_+/^R=_P<`?\%$[?QWX,^'?BW1O!O[4TWBK7=*\-:5HFH^$]-\'>/=1O=2N8
M+#3[+2=>\!6NAZ(LSR2+Y]WK?A;5'=0T]W>1!9K@_P!T6DS:C=:5IEUJEE'I
MVJ7&GV<VI:=#<_:X;"_FMXY+RSBO!%;_`&J.UN"\$=SY$/GI&)?*CW[!^8WP
M,_X(Z?L/_LX_M&Z;^TK\)/`>N:!XGT71-5T[0_"5_P");OQ#X$T'5]5DME?Q
M=HFFZ['?ZU8>([:P2]TNTVZ])HUI::E<RVFD6]\D%W'^I8Q@8Z=OI7X]XBY]
MP?GV88.OP?D$<DP\<,Y8U^QAA95\34:_=_5:%6IA:<*$8Z5*23JRJ2<G:*OR
M5YTIR3IPY=/>=K7?IMI_PQR_CGQ#)X1\%>+_`!7#;)>R^&/"^O\`B&.SDD,,
M=W)HNE7>HI:O,J2-$EPUL(FE6-S&'+A&(P?Y&?#G_!T%\2M<\0:#HLG[(W@B
MW36=9TO2WG3XL:[(\"ZC?06C3*A\$J':(3%PA90Q7!(SFOZP_C3_`,D<^+'_
M`&37QU_ZC&J5_E/_``__`.1Z\#_]C=X9_P#3U8U]UX*<%\-<68'BRMG^6K'U
M,MA@7@I/$XNA[%UJ.83J:8:O14^:5"D_WG-;ELK)ROMA*5.HJCG%2LXVW6Z?
M9KL?ZU2DE03U(S3J:GW%_P!U?Y"G5^`'$%(QPI/H"?R%+37^XW^ZW\C36Z]4
M-;KU1_'!<_\`!TC\3()[B$?L@^!V$,TL88_%K7@6$;LH)'_"$'!.,^U?V%Z!
MJ)UC0]&U=XA`^JZ5IVI/"KEUA:^LX;IHE<A2XC,I0,54L!DJ,XK_`"1]1_X_
M;[_KZN?_`$:]?ZTW@C_D2_"'_8KZ!_Z:;2OWSQMX,X;X2H<)SR#+E@)9E2S*
M6-:Q.+Q'MGAX98Z+_P!IKUN3E=>J_<Y;\_O7LK=F*I0IQIN$>5RO?5ZZ+NSJ
M****_`CB"OR0_P""H'_!6+X7?\$\/#^D>'+?3(?B/\>_&6FW&I^%?AQ#>O:6
MFDZ,CRVL7BOQIJ$$<LFEZ+-?Q26NF6<8&I:Y-:WRV2I;V-Y=P?K<WW3]/\__
M`%J_S$_^"F7Q<U_XU?MW?M/>,-?OKB\DL?BQXL\$Z4DS,4T_0_`6JW/A'2]/
MM48GR[:WAT@LB`[2\CN/OFOUKP>X'P/&W$E6CFO/+*\KPJQN*H4Y2A+%3G45
M*AAW.-I0I2ES3J2@XS:@HIKF;73AJ2JS?-\,4G;NV]/U/<?C5_P6R_X*0?&C
M6[S4)/VA-:^%^CW#SBQ\*?!RQT_P%I6DV\QS]GMM6LH9_&5\4!"I<ZSXGU.[
MCQF*>(':/,?!/_!67_@H]X`OH=0T3]L'XQZA-#)Y@A\:Z[;?$6QD)()2;3_'
M]CXELYHVVX"/`0@+>5L+$G^L#_@BY_P3B_9:\-_L??"+X[^+/AGX,^*'Q7^,
M&@S>,-6\5>,]&L/%$>B65[?75M8>&=!L-7M[G3]/M;"ULXA?-#:"YNM1:Y:X
MFE6.$)^JGQ'_`&#?V-/BUHTNA>._V9_@UJNGRQ-$!:>!-`T.[@W`_O+74=!L
MM-OK6=228YX+A)8V^9'5@#7Z9F7B?X:9+F6*R*AX<X'%9?E^(JX&>*6%RV$Z
MDJ$W1K3AAZV%E.HN>,N6=;$1J5%:4E%R9T/$4(/D]E=)VO:-M#XN_P"",W[:
M?[17[</[-7B3XH?'S2/!T6H^'_'MQX(\/^)O"FDW>@KXM@TO2;"\U6_U72WN
M[W38-1M;K4(()'T865A('^33K0IABOT*_9H_9J^$W[)/PET?X)_!31;S0?`.
MA:KXEUC3K#4-2NM:OH[GQ1KVH:_>)<:K>E[V^2TEOQINGRWLMQ>1Z38V%M<W
M5U-`]S*5_.O$.-RS'YYFF,R?`1R_*\1C:U7`X)1Y%A\,Y+V=/DC*48.RNX0;
MA%R<8VBDCBG*#FW&"46[I;66FEEIT_K6_P#+]_P<Q_L?>.-3UKX9?MC^#]%N
MM8\'Z5X:7X:?%:>PA,LWA>X@U66]\(>(=12/,@T?5?[2O-$FO-I@T^_M-/CN
M'7^U(37X;?\`!.3_`(*8?&3_`()T?$'5M;\$Z=IOC;X;^-I=.7XC?#37)Y[2
MTUN+3BZ6^J:'JUNLLN@>)K.WFFBM=2^S7UI/$PM]2TZ\A2+R?]*OQ)X;\/\`
MC#0=8\*^*M&TWQ%X<\0:;=Z3K>AZS96^HZ5JVEWT+VUY8:A9722V]U:W,,CQ
M30S1LCHQ!%?S%?MF_P#!M5\,?B!=ZWXV_8]^(,/P@U^Y:>]A^%OC>#4-;^'-
MS<2$O]ATCQ':/<^)?"-MN.8O/T_Q9;H%6W2VMD9KB/\`=?#OQ-X7J\,1X#X]
MPZ>60C+#X7&RISJX9X>=1U:=+$JBG7H5:%63='$TTU%*$G*FX<S_`)^XX\/N
M(*7$,N,.#JS^O2DJ]?"QG&&(A6453J5,/SVIUJ=6"2J4)M<WO64N:R_1K]D[
M_@MK^PK^U2VD:)#\0C\'/B#JA@MQX&^+OV/PS+)J$YCC6RTSQ+]KG\+:J\DS
MB.U$6J17-SNC46D<SF%?UT1XY426-TDCD57CD1@Z.C@,KHRDAE92"&!((((.
M*_RS?VK?V&_VF_V+/$UOX9_:$^&FI>$TU"::+0O%%I-;ZYX+\2^2"Y;0O$^F
MO-IUW)Y.V=[&9[75+>-MMY8V\J2Q)^Z'_!"/_@J[\2/"_P`7O`W[&/Q]\:ZA
MXM^%_C]X_"?P>U_Q1?2:AJO@+QE(@'AGP;'JMWYM]<>%_$<R#0-#L+BXF&BZ
MO<Z38:>D6ES^599\:^"V74LEK\5<"9K_`&MEE*E/%U<%*M3Q;^K07-4G@<71
MTK>QBI.5&K'VKBFE4E-<LM>%/%C'RS6CP[QCE_U#,*E2&'IXJ-.6'M7G[L(X
MK#U/X?M):*I3?)>2]U1U7]LM%`.?_K<T5_.7<_=ULNA^('_!PU_RC'^)G_90
M_A!_ZG>EU_+E_P`$`?\`E*1\!^Y_X1WXR\?]T@\:5_4;_P`'#7_*,?XF?]E#
M^$'_`*G>EU_+E_P0!_Y2D_`;_L7?C+_ZJ#QI7]4>''_)B^/?\7$7_JFP)_-W
M'O\`R>'A#_%D/_JSKG^B41@[@,GZ_K_2G445_*Y_21Y-\=\?\*2^,9Y_Y);X
M_P`],?\`(IZL?PZ5_ET_LJ:[HWA;]J#]FSQ/XBU*ST7P_P"'/CW\'M=UW6-0
ME6WL-*T;2?B%X=O]3U*]N'.V"TL;*WGNKF9CB.&%W/`-?ZC/QW_Y(A\8O^R6
M^/\`_P!135J_RD_`_@[Q!\1/&7@_X?\`A.S34?%7CKQ/X?\`!WAG3Y+JVL8[
M[Q!XGU6TT71K.2]O9;>RLTN=1O;:%[J\G@M;=7,MQ-'$CN/ZI^CM2I5\GXWH
MUZBHT:JP5.K5;25*G/#8Z,ZC<FHKDBW*[=M-=#^<?'*I4I9KPC5HT_:U:<L7
M.G32NZDXU\"XP26K<I62MKKY'^FPO_!37]@#`'_#7'P.X4`_\5QI><@#MYG^
M>E._X>:?\$_^O_#7'P/^O_";Z7T_[^5_$P/^"`G_``5*(!'P"T#!Y'_%YO@Y
MW_[GBC_AP'_P5*[?`+0#_P!UF^#G_P`W%>+/PO\`"=1DX^*>";2;4?KF4.[2
MNEI6OKHN^OH>G#Q#\2&X1_XA]BU&\8N7U7,=%HF_X/9W\N^C/]$X$'D="`1]
M#2TR,%8XU/4(H/U"@&GU_.+W?J?O,6W&+DK-Q3:[-K5?)GPQ_P`%+OB&OPL_
M8'_:T\;"Z^R76G_!3QEIVF3DA0-:\2V)\,:'&29(_P#6ZOK%E"`K"0^9B-7D
M*1M_G>?L+?LQ7G[7O[1.B_`ZR:>%]=\"?&#6X[R`L#8ZGX4^%/C'Q%X7GEV1
M2L]O+XQL/#UE-$$_?1W9A)7S-R_VD_\`!QC\3/\`A!?^"<&O^%(YA'-\8OBS
M\,O`!0%Q*UII6IW?Q0N638K83=\.X()F=HXREQY+.6F2*7\-O^#9?X?)K_[9
MWQ1^(,T'FQ?#SX(:G8V[E`T=MJ'C7Q%HEI%.'W*4F-AI&I6R#:X:*XGSM.,_
MU%X6XJOPMX2\9\4T6J>*EBZKP525FO:X:CAZ%%-.RE_M-9W5VFM%K='\Z^(V
M'AQ%XD\,\/U+RP\:%*&(BND,34JU:DO\2IPT[6W1^;'_``2]^/\`=_LB?\%`
M?@9XW\13R:'H:>.V^%GQ-BN28DLO#/C:=O!^NS:B"R%8?#6H75GXBN%SD2:$
MHVR`&-_],X2*<$=",YXQC&<YS7^:[_P6'_9XN/V8?^"A?QQ\-Z?9/IWA?QGK
M-C\8O`$T<)@AFT#Q]&=6NA8J>##HOB^+Q-X=5U.'ET5W.TL0/[)?AS^W]8V7
M_!'K3_VUKBXM;WQ'X3_9YO%^S74_[K4?BWX8M)O`FGZ1>ROND8:EX^M;*WOI
M56240W,]Q'#)M"-Q^-&5KB;#\"<897#VDN(L+A,KJ<JO?$8F,*^"C-QNE+FJ
MXFDUNG3:^RSI\*<R_P!7JW&'#68S<5DE7$YA3YG_`,N<.Y4<2X1>O*U3HR3Z
M\Z>S/XXO^"S?[00_:(_X*%_'/7K*]:_\.^`-3MOA%X899C-;PZ?X`$VFZDMK
MD`113^)I->O)$4E3=7%Q("QD)KYM_;._98U[]D+XF>$/A=XG2\B\0:K\&OA7
M\0M>@O$"2:?K_CCPQ;:UKFB8!(SH&IS7&BRX`S-8R'YB2Q]8_P""97P/U']K
M3_@H#\"_"/B*.7Q#8WOQ%7XF_$:>]_TG^TM&\)7;^,M??4]P`GBUN\M(["_W
M%3*NI2\DG!_6/_@Z`^'3:'^TO^SQ\3(H5CL_'WP>UOPRTBJ1Y^J_#WQ4;B\8
MML"L4TSQMH<>W>S*J*65`R%_V?!YW1X:XIX)\.<*XJC'AO$O$K1OV^'H4OJC
M>VK6%QM25M6YIM:MK\KQ655<^X=XLXXKJ3J2SS#JC)\UO9UJLGB+?X95\/"S
MM9+331_T:_\`!&?X@O\`$;_@FG^RKJ4\IEN_#?@&3X?7(+F1H4^'^N:KX3TV
M(NP!P-%TK2W5.D2NL0)"9K[>_:`UZ3PS\$OBKKD!99=,\">);E&7J&&E7(!7
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M/V/PAX7U/Q!<_O)!Y<?[G3G^>3]VA^9_E!K^??\`8.GBM_VKOA'),X1&N?%T
M08_\]+CX?^*X84^KRR)&/5F%?M'^WOI=]KG[#7[9&CZ7$]QJ6J_LL_M`:?86
M\13?<WEY\)_%D%O;*7P@-Q*Z0Y)``?.Y>H_EGZ(^#PU3AO,*LU%5,9Q?3PN)
M>TGAZ>&R[DYFO?LOK->SZ-R:U/(\*J=-Y1BZME[2IFLJ<VMW&%##..N]KU:E
MK[7=MV?YDD2^-?CU\7H(BTFM_$+XQ_$6WMDY;?J?B[Q]XCCMX8TWF1U%SJVJ
MI%$K%RBLJ_-MK_43_9A_9_\`!O[+OP'^&GP,\"6<%OH?@#PQI^D/<0Q)`^LZ
MOY2S:[X@O`JC=>ZYJ\EYJ=R[9;?<[,X50/\`,Z_8N\3Z-X)_;&_9,\9^([M;
M#P]X0_:8^!'B?7KYRH2RT;0?BCX6U35+MBS(NVWLK6>9MSJN$.6`YK_4_0Y1
M3URH_E7^F7TC\9B:57A7)Z<94<LA@L3BH0@VJ52O3='#PAR))7PM&RAJ[+$/
M1=?UO&MKV<>GO/UMRVOZ:CJ***_F$\\****`/YJO^#F;XR:AX2_93^%7P?TV
M\:"/XM?%%-0\06\4I1[S0_`.G_VO;6UP@D4RV;:_>Z7>E&1T^V:;9RDJ\*$_
MSG?\$;+3]GRU_;C\`>/_`-I3QQX+\#^`?A/IVJ_$+2KGQSJ5KI^D:EX[TG[-
M#X.@S>8BFGTW4[LZ_;(<M'>:1:3!&"$#]KO^#I'2K]M#_9,UL>=_9<>L?$?2
MW^6/[/\`;YK'0+N/+;?-\[[/!+M4-Y>S<2N[!'\HGPT^$7Q/^,VNS^&?A1X"
M\4_$/Q#:V,NIW&B^$='N];U*'3H9(XIKQ[2RCEE6WCDEB1Y2NQ6=02,BO[:\
M*<HPF+\'IX-X]Y7#-WF\<=F-.5.%3#.IB)X:4U.HXPC*.'IP2E.2Y4[IKIZV
M'2^KVORWOKVOUZ'^E9_P\Q_8"SC_`(:V^!O'/_(\:9C\/FZTO_#S']@/_H[?
MX&_^%QIG_P`77^>1_P`,!_MM?]&K?'/_`,-YX@_^1*/^&`_VVO\`HU;XY_\`
MAO/$'_R)7Q__`!`S@/\`Z+]_^#<J\O\`I]_5_2V7U2E_S\_+R\^OZ^A_J`^&
M?$V@>,_#7A_QCX5U:RU_POXJT32O$GAS7=,G6YTW6M!URP@U/2-6T^Y3Y+BR
MU'3[JWO+2=?EE@FCD'#5M@YY%?,/[$6@ZWX5_8Q_9'\+^)=+OM#\1>&_V9/@
M-H.O:+J=O)::EI&M:/\`"SPKI^J:7J%I*JRVM]I]];SVEW;RJLD,\,D;@,I%
M?3]?R[BZ4,/BL30IS]I3HXBM2A4T]^%.I*$9Z:>]%*6CMKIH>>U9M;V;7W,\
MS^-/_)'/BQ_V37QU_P"HQJE?Y3_P_P#^1Z\#_P#8W>&?_3U8U_JP?&G_`)(Y
M\6/^R:^.O_48U2O\I_X?_P#(]>!_^QN\,_\`IZL:_J#Z.7_(MXZ_Z]Y9_P"H
M^:GH8':IZQ_)G^M4GW%_W5_D*=34^XO^ZO\`(4ZOY7/."FO]QO\`=;^1IU-?
M[C?[K?R--;KU7YC6Z]5^9_D9ZC_Q^WW_`%]7/_HUZ_UIO!'_`")?A#_L5]`_
M]--I7^2SJ/\`Q^WW_7U<_P#HUZ_UIO!'_(E^$/\`L5]`_P#33:5_4GTD/]VX
M%_Z\9Q_Z;R8[\;\%+Y_E$ZBBBBOY://$/((]J_SM_P#@MQ^QIXW_`&8OVR_B
M)X]DT*];X2_'KQ)J?Q"\">*XK:9](;5]:<ZCXJ\*W5\`\,&NZ5JTMW=&SE:.
M6YTZYM[ZVC>$R^5_HDUX]\=/@'\(_P!I3X=:S\*?C9X(T;Q[X'UQ4:ZTC6("
MQMKR$-]DU32[R)H[S2M6L78R6>I6$\%U`Q90YCDD1_T+PVXZK<!9_P#VE["6
M+P.+H_4\QPT)*-2=!SC4C5HMM1]O1G'F@I^[.,IP;CS*<=\/6]C.[5XM6=M_
M)G\)'_!,W_@MC\6?V$]'T[X0>._"Z_&#]GB&\NKFS\/PW::9XZ\"R:A<-<WD
MW@W6+@OIM]ITL\L]S<>&M:AC@GN&5M/UK1<W)NO[!_V2?^"I/[&?[9CV6C_"
M?XJ6.G>/;Q`P^&?CI8_"?CB27;ODMM-TR_F-MKTD2AV8>'[W5#Y<<DP'DJ9*
M_`/]K_\`X-GO$5BVJ^+OV,/BC9:U:_Z1=1?"+XKRMIVIQHI\Q++PY\0K..:P
MOY9%/DVUGXFTK2(T,:O=>))!*WD?S+?%/X1_&G]E_P")UQX*^)WA7Q7\)_B;
MX2O+;4(8+S[1I&KV4\$HFT_6]#U6RE43P>=$L^G:SI-Y)"SQB6VN=Z9'[]C.
M$?"_Q<>(S/AK-%E7$-:$J^)HTU[*K.L[.53&Y77<>?WG:IB,'*,9MN3JU'J=
MKIT,3[T7:3U;6[VWBS_5VHK^7_\`X))_\%J]%\8?!#Q!X$_;*\?P1_$/X7WV
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MHA)9_9)L/`R#XU^'W_!?+_@IKX#TJWT:?XT^'_'UM9HL-M<_$'X;^#=7U6.)
M58!;C6M*TS0]5U-\OO:ZU>[U"]=E4/<L@*'[S*O`WB+/L@RC/<HS+*JW]I85
M8BI@L36J4*F&4IR44ZE.%>%1N"A)IJFXN;B[M:_CF8^,&2Y/G69Y1F67YA3C
M@,0Z%/%4(1JPK\L8<TO9SE3G&TG**:YHOE34O>T_LB_X+`^'/A)X@_X)T?M2
M'XOP:*VF:+\,M;UWP=>ZLD'VK3OB?IT7F_#B70)Y5^T6^MWOB[^R]*@%G)#)
M>VM_=Z9<R#3KV]5O\[_]EFVUV\_:<_9SM?"_F_\`"2W'QV^$<7A\P+.\RZU)
MX_\`#ZZ6\2VQ6X+I>F%E\AEER/D=6PP]J_:K_P""B'[8O[<,FEZ3\>/BKJOB
MO0-/OH[G0OA]X=T;2_#'A"UU$JT<-S'X<\-6-FNL:DOF2+;7^MOJ^IP+*\-O
M=1Q$1C]W_P#@@[_P27^)5O\`$[PI^VQ^T=X+U#P9X9\&K=ZI\$/!'BJR^Q>(
M/$GB.YM+C3;3Q_JF@7:B^TC1M#CN+J\\*#5[:SO]1U==.\2Z?#_9MKI=_?\`
M[#D66Q\'/#W/X<39KA:^.S/ZS/"Y;0K<\/K%;!_5J6&PL:BA.K.J[5,14C3C
M3C!)M6@Y/\LS?,)^*/&^35,ARRO1PN!>'CB,;5I*,G1IXF->I7Q$H<T::@OW
M=&,IN;;LOB2/[)$X5<XS@9]S_C3Z,9_`YHK^,3^KXJR2WLDON1^('_!PU_RC
M'^)G_90_A!_ZG>EU_+E_P0!_Y2D_`;_L7?C+_P"J@\:5_4;_`,'#7_*,?XF?
M]E#^$'_J=Z77\N7_``0!_P"4I/P&_P"Q=^,O_JH/&E?U1X<?\F*X]_Q<1?\`
MJFP)_-W'O_)X.$?\60_^K.N?Z)E%%(02"!7\KG])'E?QT!D^"?Q@CC#.[_"_
MQ\B(BEF=SX5U4!54`EF)(``R22`,FO\`+P_9%U&QTC]JW]F'5-4NX-/TW3/V
MA/@MJ.HWUW(L%K96-E\2/#5Q=W=S,Y"106T$<DTTCD+'&C.Q`!-?ZJ&M:7;Z
MUHVK:+<EEMM7TR_TNX*?>$&H6LMK*5/9@DK;??%?Y=O[<?[('Q-_8D_:(\;_
M``A\>Z#JFF:=9ZQ=ZE\._$[V]P-&\8^![N[GE\.Z]H.J[?LUZ!:J+348X9FN
M=,UBTO\`3;Z."]M)HE_IGZ/&,P=:'%W#];$4Z&+S3"X:>%C.24JL(4\50KNG
M%VYY4G7I2<4^9QDW:R;7\^^..&Q5*KPSG-*A4K8;`8C$1KRBFXPJ2J86K24V
MHOE5149I2=DFDMVD?ZD<;!D0KR"J\CZ#GZ?2GU_F?>#O^"P/_!2GP'X9T;PA
MX:_:Q\>0Z%X?LH=-TF'5]'\#>)[ZWL;==EO;2ZWXG\*:QKEZEO&!#`;[4;EH
MH$C@1EBC1!TG_#Z[_@J)_P!':^*C]?!'PG_IX!%>9/Z./%JE)0S7)I04GRR<
M\3%RC?1N/L7RMK=7=GI<]"EX[<-^SI\^6YI&?+%2BE0DE*T;I2]HKV;:6BO:
M^ES_`$G:*_D;_P"""?\`P4._;+_:S_;"^(OPX_:'^..M?$OP5HW[-WC'QKIN
M@ZCX=\$:1!:^*--^)OP?T.QU=+GPUX8T6^>6WTKQ'K=FL$UU):,E^\CP--%!
M)%_7)7Y!Q?PKCN#,[K9%F-;#U\51H8>O*IAG.5)QQ--5().<82ND[2O%:GZA
MPMQ)@^*\IIYQ@:5:CAZE:O04,0HJHI4)<DG[K:LWMK?R/Y*O^#I7Q\(_"W[*
M?PNBFPUWK_C_`,>7T'F#+K8Z=H_A_2Y?+#;L1M?ZN@9EVGS2%;*LIT_^#6[X
M>FV^'_[4OQ3FA`.J^+O!'@BPGV\O'I&D:CK.I1ES&.(GU73F"I*X_>Y=$.UF
M^"O^#F'X@GQ%^VYX`\"+,\L7P\^"6B2-'N8QV]YXMU[7-1FC52=JRFUL;*:0
MJ.4ECR200/WC_P"#=GX:GP/_`,$VO"'BB2`Q3_%WXG?%#QZS2#$LEOINO#X;
M6AP79UA*>`&G@5UB#+<-<1QLEPL\W[EG5LD^CUDF%MR5,]QU"<D_=;=?&5\P
MNE+67-0PL-NCYE='X[E/_"OXVYKB/BAE&&K*-M;>RPU'"-/MRUL1*VUFMKO3
MX=_X.?OV>!K/P[^`W[3NE6(-[X+US4/A1XJO8X_F;0O%`FU[PV+F0`DQV6LZ
M?JR6H;:L;ZO='):55K^;'1OVV/&.F?\`!/\`\7?L-,]^V@ZW\>]#^*VG7PE#
M06_A_P#L"YB\1>&26E#P6K>*=)\.:_9VD,303W6H:]<W#QR^2LO^AA_P41_9
MPMOVL/V,?C[\$O(CEUSQ%X%U'5?!4CD)]F\?>$]GBCP5)YQ*F""?Q#I-C8:@
MZ,I?2[V^@?=%+(C?Y>%S;W%I//:W4$MM=VTTEO<6T\;PSV]Q"YBE@GBE"O%+
M%*K1R1R*KHZLKJ""*^R\"\;@>).#XY+F<8UZW"F<TL=@U4:O1A*H\9@ZT>J5
M.O\`6J=[VY'*#]W0^6\8,'B\BXJEFF!E*C1XBRRIA<0X)I5)<D<-B:4MK\]-
M49I+7F7,M6?UO_\`!K]^S?)-??M!_M7:WIY^SVD6D_!3X?W<H4J]W+Y/BSXB
M7,<;J65[>V/@:QM;N(X=+[6;0G*2I7TE_P`'07PSCUS]E[]G_P"*\-MY]_\`
M#OXUWOA.2953=9Z#\2?!^IWFH3M(S*5B?6?`/AFV:*-7:26XA<A4A9A^K7_!
M)_\`9[7]FO\`8(_9\\`W-C]AU_6/!UM\0_%<;QB.X/B+XA?\51>1W2E5D2XM
M+?4+2QDBFS+;FU%LVT0A%\6_X+L_#]O'W_!,WX]K'#YD_@U_!GCR"0('DA7P
MSXKTNXNY$^5BNZQEN8';Y?W4T@W+NR/R-\7O,O&_"9]&K;#+B.AEN&FG>,<`
MI?V4I*[LE6I3J59V:UJR:ULC]-7"ZP'A%B<GE37UB62U,QKQM[TL;*V/L[;R
MA.,*47VA$_'7_@UG^(R1ZY^UK\)+FZ(>XTSX:_$31K/<Q#"VN_$GAOQ)<A"V
MT%#=>%8MRIN8/B1L)&*_K:^(>@+XJ\">,/#;)O\`[;\-ZUIBH>0TEYI]Q!$#
MW_UCKTYK^"3_`(-T/B1_P@__``4?T/PX\XA@^+?P@^)?@!ED*B*2>QAT?XDV
M@)9659C)X`,4#AHW+3-;HY^T-#-_H%$94ANXP?3\?8__`%J\SZ0.41AQUG$*
MD;4L[RS"8BVMG"KA/J%1O97<\-4;2NGO>[9T>#V+CF'`F'PLWS?5,1CL#-=5
M&4_;I6[*&)BEY(_E(^$7B2;X8?&GP'XBN2T3>$O'6EG4QRI^R6VIK9:M$=X^
M0R6;W4+$@%=Y)'!%?U/:E8Z;XH\/7VF72P7VD^(='NK&=&5)[:[T_5;*2WE4
MJP>.:*>WG8%6#)(C$$,I.?YT_P!NGX/3?"KX[^(+VTMFB\,_$":7QCH<J*?*
MBN]0E,NOZ>IP%0VFK-/-!%&-D5C=V:+RK*OZN_L'?M`6GQ=^%%CX6U:ZC'CC
MX=VMIHFK02R+YVIZ3#'Y6CZ]`I(9UE@C%G?[1^ZO[>1RL<5U;!O\YO`',Y<%
M\9<7^&V:S>&Q7]HSQ>5*H^55:N$;A.--NUY5\'[#$0L_>C2?+?<SX!Q/]C9S
MG/#6*E[.JL1*KA>9V4Y4KQDHO2\JE'V=6/=1=C_.O_;(_9U\2?LF?M-_%SX%
MZ_9W-D_@;Q?J$?AVYF$N-4\(WLQU'PCK5I-*`]Q;W^AW%E,DYRS2B5),2I(J
M_P!V?_!'K_@HUX+_`&U_V>O#?A/Q#XELX/VB_A5H6G^'?B/X6OYO*UC7['2[
M:"QTOXB:6L@5=5TS7H(T&JR6C23Z9KD=[#J$%M!<Z9<7W*?\%BO^"5MI^WQ\
M/=.\?_#"'2M(_:5^&FE7EMX6N[QX-/M/B#X=#2WO_"`Z]JDFR*V9;UYKGPQJ
M=^_V32=0O;R*YEM;#4;R>/\`A)MKO]H#]D+XQL]M-X_^!/QK^'.LO%)L-_X8
M\3Z'J%G.4DCD7Y%O=/N6B8,KB\T;6;)LXO;"XS)_K_263>.G!."P<\;1P'%^
M10AS>TM*:K<D:-2JZ>E2K@<>H1G)TM:5:,;W=/EE^X>YBZ25[5(V^3V;\T^O
MR\F?ZM%)D>O6OX@O@I_P<S?M/>#?#MCH?QF^$'PZ^,6IV5NENWC'3KR\^'VM
M:F8X]HN]7TS3+/4O#TM[.^&N)-'T_0[+D^1IT?2I?C+_`,'-/[3/B[0+O1_@
MW\&_AQ\)M3O+5K<>+=6OK_Q_JVFO("&NM*TR^M=)T)+N'K;OJMGK%GO^:>PF
M4;#^/_\`$"?$7ZY]5_LW">RY^7Z]_:&'^J<M_P")\7UGEMK;ZMS]HLY?J=:]
MO=];]#^Q;Q7^T)\$/`OQ(\'?!_QA\4_!/AKXG_$&VOKOP7X(UG7[&PU[Q'#I
MQA6Y_LZTGE0R2GS@;6W=DN+\1736$5RME>&#V($$9'2O\K/3KS]IK]L3X]V%
MW8:A\2/C7\?_`![XAMY;#48;K4M7\4W&K-/YT%Q!=Q.J:%INDX\Z*2)].T;P
M_86^^/[#8VG[K_23_88^&_[1'PF_9E^&W@7]J3XGP?%KXQ:-IKQZ]XG@M8D-
MI9,X&C^'+G5D2*7Q5>Z!8+'8WGBN]@AO]:G5Y[LW,BF^NN3Q%\-</P%@\IE+
MB'"X_,\9%QQF6Q@Z=:E*TF\10BN9O"1:5'FK^SG.IK"Z;C!5\.J,8OVB<GO'
MKTU6FWK^FOPE_P`%Y/V7-=_:1_80\5:MX+TB?6O'/P+UNQ^+6E:;:1M+?:CX
M<TN&>P\>6EE&N3)<6OAB\NO$2Q*IEN!X?-I;J]Q<QQM_%W_P3=_;#N/V'/VL
M_AS\<;BTN]5\'0RW/A3XDZ18%3?7_@'Q)Y5IKDVGQR,D,VJ:.4MM<TZ"62%+
MNZTU+%[BVCNI)X_].2YMX+RWGM+J&*XMKJ&2WN+>>-98)X)D,<T,T;@I)')&
MS(\;@JZL58%217\/G_!7K_@B9X[^"7BCQ?\`M(?LJ^%M2\:_`[6K^]\1^+_A
MWX>LIM0\3?"2ZO9Y+O4+C2](M%EOM:^'\<CRW"7%G!+=^%;0F/4XFTJV;5(_
MMO!GC'):F59IX=\45:='+\X=;ZA7K35.E*>,IQHXC!RJMI4JDY*-7#2DTG5<
MX7YG!2VPE6/*Z,W:[TOUOHUZ]KOT/[4_AS\1?`WQ;\%>'?B)\./$ND>,/!?B
MO3;?5M`\0Z)<QW>GZA97*!T=)$^:.5,F.YM9ECN;2=9+>YBBFC=%[8@?W1^7
M^<?6O\QS]CC_`(*1?M;?L(ZM<1?!;QY(/"%U>-/K_P`)_'%G/XA^'NJ78`26
MX?09KFSO-!U1@J+/JGAK4-#U2X6&&"]N;FVB6WK]F++_`(.B?CS'I"V]_P#L
MO_"R[UORMK:K;>-?%%EIYFP/WHT>33+N94R#^Y.K,?F'[WY>?(S[P`XQP6-G
M')%A<ZRVI4OA\1'%4<+7C2D[Q^L4JTX14H*RE*C.I&=FXQ5^51/!U$[TW&4-
M;:ZK7;S]3^TM3GMC'\^_:EK^*[]E;_@XD_:%\6?M=>!O^&E&^'_AW]G3Q:[>
M"M9\,^$/#2:99^"[W6[ZR31_B!<^(M3GU?Q-?3:-<QK::O%<:O!H']BWVHW@
MTBWN[:WNH?[2[:X@N[>"ZMI8[BWN88YX)X762&:&9!)%+%(I*O'(C*Z.I*LI
M#`D$&OS?B[@C/N"<5A,+GM"E3GC<-]9H5,/5]O0DE+EJ4O:J,4ZU%N/M8JZ2
MG!J4D[F%6C.DTI6U5U;7U1YS\:?^2.?%C_LFOCK_`-1C5*_RF?!%Q!9^,_!]
MU=2I!;6OBCP]<7$\AVQPP0:M9R2RR$_=2.-6=B>B@FO]9GQ%HMGXD\/ZYX=U
M`,UAKVD:EHM\J'#&SU2SFL;H*3G#&"=P#@X..*_S#OV[OV,?BG^Q'^T!XT^%
M/C_P[J-KX?36;Z_^''C%;.X_X1SQOX*NYWN-$U71=4\L6D]Q!921V.M:>DIN
M]'U:WN["[16C1Y/V[Z..88&-7BG):^)IT<9F5#`U<+3G*,9UJ>'CC*5?V2E\
M<J?UFG)QC>5G?8Z\#)+VD6]7RM?*_P!^^Q_I[Z-JVF:]I.F:UHU];:GI.K6%
MIJ.FZC9RK/:7UA>P)<6EW;3(2DL%Q!(DL3J<,C`UIU_ED>"OVW/VQ_AOX>T_
MPE\/_P!JG]H7P5X7TF!+;3/#OA;XP>/=#T73[=,[(++3=.UVWM+:%-S;8X8D
M1<G`&:ZO_AXO^WY_T>I^U-_X??XE_P#S25SU?HU<0*I4]AQ%D\J//+V3JT<;
M"HX7]WVD84IQ4[?$HSDK[,3P,KNTXVZ:,_U#*:QRC$?W6_D:_P`_;_@E?^W!
M^V5\2?\`@H-^RYX%^(7[57[0GCCP7XD^(%Q8^(/"GBSXO>/-?\/:W9+X7\07
M(M-5T?5-=N;"_MQ<00S"&Z@EC$L4;A=R*1_H%,,J1Z@CT[5^2<=\#8[@#-<)
ME>88W"8ZKBL%#'QJX.-94XTY5Z]!0DJT(2YU*A*3LFK-:WNES5:3HSBI-.]I
M75]K_P#`/\C+4?\`C^OA_P!/=R/_`"*]?ZPOP<\5:#XW^$WPS\7>%]2M=8\/
M>)/`7A+6='U*RGAN;:\T_4-"L;BWFBF@DEA?,;@.$D;8X9&.Y2*_S?/^"E_[
M#_CC]AW]I[Q_X$U+1-2'PO\`$&OZMXF^#GBY[6=M)UWP/JU_<7>EZ8-1V?9G
MU[PU#*NB:[9B03I=6@O?)2TO;5G^?_AQ^V!^U=\'O#\7A/X4?M*?'3X;^%[=
MF>W\.^!_BIXU\,:+`SL7<PZ9H^M6=G%N=F=MD*Y9B3R:_JOCO@B'BUD/"V8Y
M#G.#HQP>'JU:-2O&=6A6HXZEA/:0FZ'/4I5Z,\+&+A*FVI<\)\DHGH5J2Q$*
M;A*R6JNM+-+U[=S_`%3**_R\_P#AXO\`M^?]'J?M3?\`A]_B7_\`-)7U!^Q%
M^WI^V[XP_;1_9#\)>*_VNOVD?$OA;Q3^U!\`O#GB7P[KOQH^(6J:)K^@:W\5
MO">F:SHNL:9>^()K/4=*U73KJYL=0L+N&6VO+2>:WGCDBD=3^08_Z.W$67X'
M&X^IGV2SIX+"8G%SA"&.YYPPU&=:48\U!1YI1@U&[2NU=V.=X*:3?/'3R9_H
MV54MK^QO'N8K2\MKF2SG-K>1V\\<SVMRJ)(UO<K&S&"=8Y(W:&4+($=&*A64
MFRYVHQP3A2<#J>.@K_-=^.7[=G[6_P`,_P!M?]HKXN_#'XG?%KX(Z_XL^+GB
MW4G\/23ZKH\4FE66L75AH%IXE\#^(K>31]0,.DVMIYEAKFB744<N\&$$"OSK
M@'P_QO'V(S/#8+'X7`U<NPM+$1>*4G"O4JU'"%%<CYXWC&<G-1FHM13C[R9A
M1HNLY)-1LM+ZWVN?Z4?&>ISD<9Z?AD?CUK^57_@Z'TCX5CX3?LSZ[<?V7%\:
MA\1_$.EZ+Y8B36+SX9/X8O+KQ2;S8!-/IVG>*8/!@L#<LT=M<ZEJ`LMK75[N
M_);3O^#AO_@I78Z`=&N?&WPNU?4#'Y8\5:E\)_#T>OJVP+YRP:3)I?ACS<@R
M$-X<:'>S?N@@1%_,KXJ_&3]IK]M[XN0>(_B3XC\=?'7XL>)9XM*T:PL]+.H7
MA$\X%MHGA3PCX8TZWTS1[$SR#R=)\/Z196GFNTGD>8[N?VKP]\&.)N%N*,#Q
M#GF897@L#E3K5I/"XR=2>(YJ-2E[.4IT:,*5!J;E5E4E=QCR\EWS1ZZ&%E3J
M*<Y+EB^F[_R[6/GVST[4M0\S^SK*\O/)V>=]DAGF\OS-_E^9Y*-MW[)-F[&=
MC;<X."O[M/\`@D7_`,$?]*_9X^!>N^(/VJO!.@:U\8/BU?:'K5_X4ODT[7(_
MA[H&B6VIIHGA^6[5;NR;7)_[:O;[7_L$DD$,[VVG_:;IK#S:*VXG\:\CP^?9
ME0P6"698:A7C1IXZDX.GB'3I4H5)TY->]356-2,)[3C&,EHU=5,3!3DEJD[7
M7HO^#_6_[S>-/A[X$^)&CR^'OB!X.\,^-M#F#B32O%.B:=KMB?,7:S"VU*WN
M(D<KQYB*KX`^;@5\,>)O^"27_!.'Q9=F^U7]D;X20W3RK-))HNCW?AY99%#C
M,L>@WVG1RJV\[UD5D<A"ZL40C]&**_F#!YQFV7)K+\SS#`IO6.$QN(PT7YM4
M:D$WZH^>Q>597CW?&Y=@<7+^;$X6A6EZ*52$I)>2=CY"^%/[`O[%_P`$;^'5
M_A;^S/\`!_PAK%NP>'6;'P9I5QJ\;J_F)(FHZA!>7B2Q/S#(DP>(!1&RA1CZ
M\`"@```#H!2T5ABL;C<?4]MCL7BL95V]KBL15Q%2W;GK3G*WE>QOA<%@\%#V
M>#PN&PE/^3#4*="':[C2C%-^;5PHHHKE.D\V^+'P=^%GQV\&7OPZ^,G@+PQ\
M2O`NHW>GW]]X4\7Z7;ZQHEW>:5=)>Z=<SV-RK1/-97<<=Q;N1F.5%=>17B?P
MK_8-_8S^!_C;2_B1\(/V:/A!\.?'NBPZC;Z3XM\)^#M,TC7-/AU:PN-*U.*U
MO[:-9HDOM.N[FRN54@2V\\L;?*QKZUHKLI9CF%##U,)0QV,HX2MS>VPM+%5Z
M>'J\\5&?M*,)JG/GBE&7-%\T4D[I(XZN7X"MB*>+K8+"5<52Y?98FIAZ,Z]/
MDES0]G6E!U(<DO>CRR7*VVK-L****XSL`C/!KR;XM_`?X,?'K0D\,_&CX7>!
M_B?H,3M)#IGC7P[INO6]N[[=[VWVZ"5[9I-J^8T#QF0*H?<`*]9HK6C6K8:K
M&MAZM6A6@^:%6C4E2JPEWC4@XRB_--,RK4*.(IRI8BE3KTIJTZ5:$:E.2[2A
M-.,EY--'P/\`\.L_^"<_7_AC#]GW/K_PKS1O_C-)_P`.LO\`@G/_`-&8?L^?
M^&\T7_XS7WS17I_ZQ<0?]#W./_#GC?\`Y>>;_J_D/_0ERG_PW83R_P"G/DCY
MC^"_[%W[)_[.GBF_\;_`K]GWX6_"GQ=J>@W7A;4/$7@CPKI^AZK>>';[4-+U
M:[T:XN[2-))-/N-2T32;V6W8['N-.M9"-T2U].445YV)Q6*QE5U\9B:^*K-1
MBZV)K5*]5QBK1BZE64IM16D4W9+1'H8?"X;!TE1PF'H86BFY*EAZ4*--.7Q-
M0IQC%-[MI7;U>I\F_%;]A+]C?XY^-+_XB_&']FSX1?$CQUJEM86>H>*_%WA#
M3=8UN\M=+M8[+3K>>^N8VE>*RM(H[>W0G$<2A5%>_P#P\^'7@7X2^#-`^'7P
MS\)Z'X&\"^%K1['P[X4\-6$.EZ'HUG)<SWDEOI]A;JL-O')=W-Q<NJ*-\TTL
MC99V)[.BM*N/QU>A2PM?&XNMAJ'+[##5<36J4*/+%PC[*C.;IT^6+<8\D5:+
M:6CL12P."H5ZF*HX/"T<36NJV(I8>E3K5>9J4O:5804YWE%2?-)WDDWJ(RJZ
MLC`,K`JRD9!!&"".X(ZU\,:E_P`$R/\`@GSK&JZAKFJ?L>_`2_U?5=1NM6U'
M4+GX?Z-)<WNI7US)>7=[<2-#F2XN+J62>5SRTCLQZU]T4487'X[`^T^I8W%X
M/VJ4:OU7$UL/[6,;\JJ>RG#G2N[*5TKNV[#$X'!8WV?US!X7%>R?-2^LX>E7
M]G)V;</:PER-\JNXV>B(XHHH(HX88TBAA18XHHU"1QQHH5(XT4!41%`554!5
M4```"N9\;^!_"'Q*\)Z]X$\?>'-)\7>#?%&GS:3XB\-:[9Q7^CZSIMQCSK'4
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ME^SS8?M"?#*\T2#R;3QCH1?5_!NJ2*,0ZE$G[W3KE@-QL-6@4V<XS^XE:WO`
MKM;"-_Y\/`?CCXB_LX?%!=8TP76A>*_"FJ2Z9KVAW\;I#?0V]RJ:GH>K6KA6
MDM;M$,1==DT),5W9S0W$<$Z?U8U\.?M7_L8>&?C]9S^)O#K6?AGXH6D"BVUA
MH2+#Q!%`F(].\0K"OFL0@6&TU1%FN;-0B/%=6R+`O\W>,WA3F'$-?"\:\&SE
MA>,,G]G4<*,_8U,RIX=\U%TJETEC:%N6FYOEK4OW,GI!'PW&7"N(S&I2SK)Y
M.CG&#Y7:#Y)8F%.SARRT2KT]5%R=IPM3>T;>L?L^?M+?#_\`:$\.1ZAX<OH;
M#Q'9PQ'Q#X1OIT76-)E<!3(L;",WVG2296WU&V1X'.(I?*N`\2\=^U#^PC^R
MI^V-HYTOX_?"/P]XNO883!IWBRV%QH/C?1P`?+.F>+M$FL=;A2)CO6SFNY]/
MDYCN+.:&22)_P*\4>"_C%^SIXU@&KV7B+P%XET^=GTK7+*2XM;>]$94F?2M5
MM_\`1=0MV&P31QRR`*XBNHE)V5]J_"K_`(*:_$SPS!;Z9\2_#6F>/[")4C&K
MV$Y\/^(PH`!DNG$5YI>I%5'RHMEILKL2TMXY/'F\`_2863UZ.7<<T\SX3XER
M^2HU,UPU/$4:<ZD+1=2M2I6Q.$J27O5%&-2A/5PM%J"X\F\1:5)K!<14JV6X
M^C:%2O[*?LIR5DW4IQ3J49/>2490=KJR:BOD7X@_\&NWP1U769[KX8_M1?$[
MP3HTTTDL6D>,/`_ACXAW-K&[2-]GAU72]6^'A>*+=&D#W-E-.(X\3RW$KF86
MOAM_P:]?`71M6CN_BM^TQ\4_'NE13))_9/@WPCX8^&[7$:8)M[O4=2O_`(B3
MM#*05D:SBL;CRCB&>&0B9?UOTC_@IU\!+Z`/J>D>.=$F"_/!<:3:7A#@@%5?
M3[ZY5AR2&.W@<@$XJQJ/_!37]GVTMFELK+QOJLPW8M;?18;:1CQ@![Z\MH><
M\9D`&#DCC/\`3"^EO2GA$EXMX=473M?VE%5^6R7Q_4EB.:VE[\^NFK/M%QMD
M+ASK/,):W-?G?-LG?E<>:_=6OY7/:?V8_P!B7]F']CO0GT+]GSX2^'O`WVJ!
M+?5=?076L>+M<52K$ZWXKUNXU#7K]&D42_9Y;[[)&X406T4<<:)WGQN_:`^'
M7P%\-2:]XUUB-+R>.5-$\.VTB3:WKEV@R(;*S!WB)"5-S?3".SM591++YDD,
M<GY5_%/_`(*?^-]=@GTSX5^#['P;;R^9'_;_`(AG77=;V,`5DL]/@6VTK3IQ
M\RLUR^MHRDF,02!7'PQHOAOXT?M+>.)FL(/$?Q"\57KJ=0U2[DFN+;3K=W(#
MWM].PLM+LHB6\J'?#&<,EO"[Y2OYMXZ^DOA\QQ%;`\$T\QXPXGS"?LJ>8XBE
MB:U"%66D:L8U4\3C9Q?P0M"DK7E/E7*_C\W\1</)O"</TJV:YA5]RG5]E4=&
M,GHI1A;VE9KI'EC%6UDUH_TV^!/_``4DC\0_$#7-(^,5KI_AKPKX@U19/"&J
MV<3&W\+P%(+:'2=<N$7S+JUF\L7LNLRQJ;>]N+P2K#IGV:&P_6FTO+/4[6&[
MLKFWOK*ZACGM[JVEBN+>Y@F0/'+#+$6BDC=&5D=&965@02#S_.Q\7_V!_C5\
M*O#VG>);6W@\>V)T^.Y\00^%;6ZGOO#]YR9X/L1#76IV$*[3_:-K$I/[QIK.
MWBB\U_-?@W^U?\:O@88K#PMXA_M#0()BTGA+Q/'/J>BKM8"6&"'S[>]TW)'S
M#3KNT`?+%26??\9POXU\7\!8MY%XMY1FCA7F\1ALW]@OK5*->2J.$HPM1Q="
MFYVBZ$_:T$O9.,THJ/DY7QIFV0U?J'%V#Q2YY.I2QC@G5A&HU)QDH^Y5IQOI
MR24Z=N1IZ*/ZG?M,?\$B?V"_VJ;N_P!=^('P5T_PYXTU$N\_CWX97EQX"\4/
M<R##7=W_`&0/[!UFY]'\0Z%J\8.6,98DU^8.J_\`!K]^RO+J(DT7]H;]H.PT
MG<A-GJ<7PXU?42@<EU_M.T\'Z);!FB(17_LC"R`R%'4^6/T-\%_\%3_!EU;P
M1>/_`(<>(=%OL*DUUX<O['6M,=N`\PBO?[*O;96.66`+?,JG:9W(W'UE?^"E
M?[.;!6,GC!3@$I_PC\IVDC)4E9B"5Z9!(XR"17]5</?2FRC"8*G'*/%*6#PW
M+%1PN*Q-:,J"LDJ:HXVC-TN5:<M.T5KRZGZ#A^-^'ZM-2IYUAXII/EJRG3G&
M^MG&I%23Z/=;JY\L?`#_`(($_P#!/'X'7ECK>J^!_%OQS\1V$J3P:E\9O$R:
MSIL,X(8F/PEX:TWPIX1N80Z@PQZSHNKS0``K<L^Z1_V?M;6PT?3K6PLH;73=
M-TRT@M+2U@6*VM+&QM(5AM[:"-`D4%O;P1I%#&@6..)%50%`K\Q/%G_!4;X;
MV5O*G@GP'XJ\1WPSY+ZM<V'A_3">0#),G]JWQVX#&-=/`=3@2HW(^#_BK^V%
M\9_C2+G3]6UF+PWX:N"RGPSX66XT^QF@8X2+4;M[B:_U)BF%F\V>.VE;>4M(
M8V\E?@N.?I0<-5Y.M6XBS#C;-(J7U>AAZE>K0A)V33Q%>,</AX-VYW1A-NVD
M)25CRLS\0LBPT;4<5+,\19J%+#*3A=?SU914(J[U<5.6^FQ_1LDB2('C99%(
M!5D8,&!Z$,N0?7(KS;XI_!GX3?&[P^WA3XO_``Z\&_$CPXS^:-'\9:!INO64
M<N,&6"/4+>8P2%?E:2!HW9?E8D<5^(_P3_:H^+?PL@M-+T[64U_P[;^7&GA_
MQ()]0M((`H7RK&Y6>&_L%13^X2&Y-M$0BFVDB7RZ_1?PC^W/X1UJ"%/$?A'7
M-&O&4>8VGW-IJUB#CDK(XT^ZP2.$-HV!UD)Y,\)>./">=1HU9XS$\/9G#E<J
M6)]K#V56V]#&4$DUK[LG[*5M7&+T-LJXUR?'PBZE6>!Q%ES4JRE92Z\E6"<9
M+M?E?=+4K_\`#K?_`()V?]&:_L__`/AO-$_^,4?\.M_^"=?_`$9K^S__`.&\
MT3_XQ7MEC^TY\-M1*_9VUKYAC#Z:ZCUZ[\=".GK710?&;2=2(72=+O96;`$E
MV\5O&`<'.U3-(V,_=*QYQ]\5^K4O$AUTG0XPQ]>]K*EFN.FW>VR57S6Y]%#-
M\)4_AXZ,^RA.4F]MK>J/(OA__P`$^/V(_A5XRT#XA?#?]EWX,^"O''A:\;4/
M#GBGP[X)TG3M:T6^:WFM6NM/OH(5EMIS;7$\)D0@^7*Z]&-?8@&,\GGU[?2N
M6\/:K=ZIF:YVC*Y"1J5C7(/W02S$]/O,?;L!U5==3,L5FO)B<5B\5C)*/)"I
MBZ]7$35--R48RK2G*,>:3?*FDFV[7;.M5/:I3YI23V<FV[;]3SGXF_"#X6_&
MCPY+X0^+/P^\(_$7PQ,69]$\8:#IVO6`=EV-)%#J%O.()F3*&:`QRE"5+E3B
MOD__`(=;_P#!.S_HS7]G_P#\-YHG_P`8K[VHKKPV;9K@J;HX/,\PPE)R<G2P
MV,Q-"FY/>3A2J0CS.RN[7=BU.:5E*2792:7X,^"?^'6__!.S_HS7]G__`,-Y
MHG_QBM[PK_P3?_8.\#^*/#?C7PA^R=\#_#GBWP?KVC^*/"_B'2?`FCVFJZ#X
MB\/ZA;ZMHFLZ9=QP"2UU#2]2M+:^LKB,AX+F"*5"&4&OMBBMI9_GLXRA/.LV
MG"<7&<)9CC)1E&2M*,HNLU*,DVFFFFG9Z#]I4_GG_P"!2_S"O`OB_P#LK_LX
M?'Z-H_C/\$OAI\269=ANO%?A'1]3U`)M"*%U.6U&HKY8`\K%U^Z(!CVD9KWV
MBN##XG$82K&OA<17PU:'PUL/5J4:L?\`#4IRC-?)HE-K5-I]T[?D?EK/_P`$
M6?\`@F5<ZE_:;_LJ^$$F`<""#7_'-MIQ\PLQSI5OXICTXE2Y"$VQV`(J86.,
M+]@?!K]DG]F7]G@!O@I\#?AK\-[C88SJ'A?PII=EJSJP8.'U;R'U-_,#,)=U
MV?,!(DW#BOHJBO1Q?$.?X^DZ&.SO-L90=KT<3F.+KTG;:].K6E!VOI=%.I-J
MSG)KU?X]_F(5!ZBBEHKQR`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`I#T/T-%%`'+^*/!GA3QUH\^@^,?#VD>)='
MN3^]T_6;"VO[8OM(65$N(W\J>/<3%<1%)H6^>*1&`(_./XU?L&?`"VM;G5]!
ML?$_A>=O.F^S:)KJ&R4HA8(EOK&GZMY<9(Y".&QT8445^->+^391B\DJ8K%Y
M5EN*Q4/=AB<1@<+7KPCR_#&M4I2J17DI)'R?%N#P=;+YU:V$PU6K&RC5JT*5
M2I%76D9RBY)>29^-/C[PU8^%M>DTO3YKR:W2(.'O'@DF),DB\M!;VZ8PHZ1C
MG/-+\/\`PQ8>+->32M1FO(;>0)N>R>"*?F2-.&FM[A.C'&8SSCW!**_AV.7X
M#ZXH_4<)R^U:Y?JU'EM?:W):WD?A?U?#^V2]A1M[2*M[*%K76EN4_9'X)?L'
M?`&ZMK36=>L?$WBF?RX+DVNN:Y$+!F=0S1O;Z/I^D^9%EONN[-@#YNI/Z/\`
MA+P5X2\!Z1#H?@WPYH_AK2+<_NK#1K"VL;?<6PTLBP1H9IY/O2W$QDGF<EY)
M&<EB45_<?@]DV3X3(:>+PN59;AL5.*C/$X?`X6CB)QM%\LJU.E&I*-];.35S
M]RX2P>#HX"G5HX3#4JLHVE5IT*4*C7+#1SC%2:\FSIG&6`/(.,@\@\]QTKYG
M^+'[)OP&^*DESJOB;P+86^N3^9+/KWA\G0M6N)2"QFNY[!8XKV<G&9[V"XFP
M%3S-@"T45]]Q9EN79EDN-I9C@,%CZ<*%2<*>-PM#%0C-))3C"O3J1C)+:22:
M[GOYGAL/B<)5AB</1Q$5&ZC7I4ZL4[K5*I&23\[7/QW_`&B_V9O`'PJ>27PQ
MJ/BJ17BNYU@U34-+NH8C"<(D9@T6TG*`=?,FD<_WZ^#\G!]@N.F.<9HHK_.[
MB'+,MHYEB(4<OP5*"K22A3PE"$4N9:*,::2^X_G?,<-AX8NK&.'HQ2>BC2II
M=>BBD?>_[.'[,_@#XJ)%<>)M0\51@"TD:#2]0TRUAD\U4+JYFT6ZG"_,0/+F
M1@,?-Z_L5\*_V6O@=\*Q:ZAX8\$6$NL0!6AUS7"=;U:%V4DR6US?"1+27!*B
M6TB@DV,R%RI(HHK^B/`K(LDJ59XBID^53Q%.*G3KSR_"2K4YJ,;2A5E1<XR7
M249)^9^A\#8'!2<JDL'A74BHN-1X>DYQ=J>L9N',GYID7Q$_9;^"7C-KK5K[
MP=:Z3JTI:XFU'PVW]ASSSL2SRW$5H@LYY9'R\LLMJTLKDM*[DFO@CXA_!WPO
M\/KN9-$O-<G2.)Y474KJQG"_)(X0&WTVU8H"H`W,6QU8GFBBOHO$C*,IP^90
MJT,KRZC4J6G4J4L%AJ<YR:NY3G"E&4I-[N3;?5GH\2X3"4\0IT\+AX3EK*4*
M-.,I-MW;DHIMOJV[LI>$QAH_JWZ8%?>7PR\(:7?6]O<SRWI;;&=B2Q+'D\?\
M^YDZ?]-***[>"Z%#GH_N:6R_Y=P_N^161PASKW(_&OLK_(^F+'3;/3K<1VL6
MP``98EW."!RQYR<<UI445^^4DHTX**226B222^2/T"*M%):*R_(****T&%%%
0%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
